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The k-opioid receptor (KOP) mediates the actions of
opioids with hallucinogenic, dysphoric, and anal-
gesic activities. The design of KOP analgesics devoid
of hallucinatory and dysphoric effects has been hin-
dered by an incomplete structural and mechanistic
understanding of KOP agonist actions. Here, we pro-
vide a crystal structure of human KOP in complex
with the potent epoxymorphinan opioid agonist
MP1104 and an active-state-stabilizing nanobody.
Comparisons between inactive- and active-state
opioid receptor structures reveal substantial confor-
mational changes in the binding pocket and intracel-
lular and extracellular regions. Extensive structural
analysis and experimental validation illuminate key
residues that propagate larger-scale structural rear-
rangements and transducer binding that, collec-
tively, elucidate the structural determinants of KOP
pharmacology, function, and biased signaling. These
molecular insights promise to accelerate the struc-
ture-guided design of safer and more effective
k-opioid receptor therapeutics.
INTRODUCTION
The k-opioid receptor (KOP) and closely related mu-opioid re-
ceptor (MOP) and delta-opioid receptor (DOP) are G-protein-coupled receptors (GPCRs) for endogenous opioid peptides
(dynorphins, endorphins, and enkephalins, respectively). KOP
was originally identified as the receptor for hallucinogenic syn-
thetic (Martin et al., 1976; Pfeiffer et al., 1986) and naturally
occurring (Roth et al., 2002) opioids. KOP also functions as the
principal opioid receptor subtype responsible for mediating the
myriad actions of dynorphin and dynorphin-related peptides on
stress, addiction, emotion, and perception (Bruchas et al.,
2010; Chavkin et al., 1982). In fact, KOP has emerged as an alter-
native molecular target for the creation of safer analgesics (Bru-
chas and Roth, 2016) given the side effects associatedwithMOP
agonists including respiratory depression, tolerance, depen-
dence, and constipation. Recent studies have uncovered further
potential therapeutic areas for KOP ligands, such as affective
disorders and addiction-related behaviors (Bruchas et al.,
2010; Bruchas and Roth, 2016). Consistent with the therapeutic
promise of biased agonism (i.e., the selective activation of bene-
ficial pathways over deleterious signaling pathways) (Kenakin
and Christopoulos, 2013; Urban et al., 2007), activating Gi/o pro-
tein-mediated pathways downstream of KOP, while avoiding
arrestin-mediated signaling, hold promise in designing safer
KOP therapeutics devoid of the dysphoric and hallucinatory ac-
tions of conventional KOP agonists (Brust et al., 2016; Spetea
et al., 2017; White et al., 2015).
As recently demonstrated for other GPCRs, structural insights
from active and inactive receptor states can be leveraged in
virtual ligand screening campaigns, and have already yielded
new tool compounds (Wang et al., 2017), some of which show
promise as safer analgesics (Manglik et al., 2016; Spahn et al.,
2017; Zheng et al., 2017). Even though antagonist-bound
inactive-state structures of all four opioid receptors (MOP, KOP, 
DOP, and nociceptin [NOP]) (Fenalti et al., 2014, 2015; Granier 
et al., 2012; Manglik et al., 2012; Thompson et al., 2012; Wu 
et al., 2012) have provided unprecedented molecular insights 
into opioid receptor structure, a molecular understanding of 
KOP activation remains elusive. This is largely due to our insuffi-
cient molecular understanding of active-state GPCRs, because 
obtaining crystal structures of such GPCR states remains 
challenging.
To facilitate a deeper understanding of KOP function and, 
more generally, of GPCR activation, we report the active-state 
crystal structure of KOP in complex with a high-affinity agonist 
and an active-state-stabilizing nanobody (Nb) at 3.1 Å resolution. 
A comparison with other opioid receptor structures identifies 
residues critical for KOP activation and illuminates key molecular 
determinants of subtype selectivity and signaling bias.
RESULTS
A Nanobody-Stabilized Active-State KOP Structure
We adopted nanobody technology to obtain an active-state-like 
crystal structure of KOP, since structure determination of 
signaling complexes remains incredibly challenging. Nb—small 
single-chain antibodies—have facilitated the structural charac-
terization of high-affinity agonist states of the b2-adrenergic 
(b2AR) (Rasmussen et al., 2011a), M2 muscarinic (M2R) (Kruse 
et al., 2013), and MOP (Huang et al., 2015) receptors, by 
mimicking the binding of signal transducers. We raised nano-
bodies by injecting KOP liposomes (Vardy et al., 2015) bound 
to the agonist salvinorin A (SalA) (Roth et al., 2002) into a llama 
and used phage display to identify nine clones from these im-
mune libraries (Pardon et al., 2014). To verify KOP-nanobody 
binding, we measured nanobody recruitment to unliganded, 
agonist-bound, and antagonist-bound KOP using biolumines-
cence resonance energy transfer (BRET) (Figure 1A). Only the 
identical clones Nb6 and Nb7 (Nb6/7) from the KOP-SalA library 
as well as the MOP active-state-stabilizing nanobody Nb39 
(Huang et al., 2015) bound KOP in our assay (Figures 1B and 
S1A). Consistent with a preference for inactive KOP, we 
observed strong basal BRET between Nb6/7 and unliganded 
KOP (Figure 1B); we also found that the selective KOP agonist 
SalA reduced the BRET ratio, while the selective KOP antagonist 
JDTic (Thomas et al., 1998) reversed SalA’s effect (Figure S1B). 
Remarkably, Nb39 was recruited in an agonist- and efficacy-
dependent manner to KOP by the full agonist SalA and partial 
agonist diprenorphine, while the antagonist JDTic had no effect 
(Figure S1C). These findings implied that Nb39 stabilizes an 
active-state conformation of KOP as reported for MOP (Huang 
et al., 2015).
To further test this hypothesis, we used the extended ternary 
complex model of GPCR activation (Samama et al., 1993), which 
predicts that high-affinity agonist binding sites should increase in 
number when a G protein (or its nanobody mimic) allosterically 
stabilizes the activated receptor state (Figure 1C). We confirmed 
this prediction via saturation binding studies wherein Nb39 
increased KOP high-affinity agonist binding sites more than
6-fold for the full agonist 3H-U69,593 and 10% for the weak 
partial agonist 3H-diprenorphine (Figure 1C). Additionally, Nb39attenuated the agonist dissociation rate by approximately
6-fold, whereas Nb6 accelerated agonist dissociation >2-fold
(Figure S1D). Importantly, BRET studies revealed that Gai1
dose-dependently inhibits KOP/Nb39 interactions (Figure S1E;
Table S1), while b-arrestin2 modestly promotes Nb39 binding
to KOP (Figure S1E; Table S1), confirming previous suggestions
that b-arrestins and G proteins recognize different receptor con-
formations (Wacker et al., 2017a).
To identify a ligand suitable for crystallization of a Nb39-stabi-
lized KOP active state, we tested several ligands in the BRET
assay and found that the epoxymorphinan MP1104 (Figure 1D)
(Váradi et al., 2015) displayed the highest potency and efficacy
for Nb39 recruitment to KOP. MP1104 has picomolar KOP bind-
ing affinity (Figure S1F) and is a potent KOP, MOP, and DOP
agonist (Figure S1G).
As Nb39 and MP1104 cooperatively promote a stable active-
state KOP, we were able to determine the X-ray crystal structure
of a KOP-MP1104-Nb39 complex (Figure 1E). Crystals were ob-
tained using a newly engineered human KOP construct with an
N-terminal thermostabilized apocytochrome b562RIL (BRIL)
(Chun et al., 2012) to increase receptor expression, and to facil-
itate crystallization (see STAR Methods for details). Binding and
functional assays showed that this KOP crystallization construct
retains high affinity for MP1104 and elicits MP1104-mediated Gi
activation similar to wild-type (WT) KOP (Figures S2A and S2B).
The structure of the KOP-MP1104-Nb39 complex was deter-
mined to 3.1 Å resolution in the space group P21 with two mono-
mers per asymmetric unit (Figure S2C and S2D; Table 1). While
we observed strong density for KOP, Nb39, and MP1104 (Fig-
ure S2E), no electron density was observed for the likely disor-
dered N-terminal BRIL fusion protein as reported for the NOP
receptor (Thompson et al., 2012) and the nanobody-stabilized
b2AR structures (Rasmussen et al., 2011a).
Large-Scale Structural Changes in Active-State KOP
Next, we analyzed overall helical movements by comparing the
inactive-state KOP-JDTic structure (PDB ID: 4DJH) (Wu et al.,
2012) and the active-state KOP-MP1104-Nb39 complex (Fig-
ure 2A) and observed substantial rearrangements in the relative
positions of the helices. These include an overall contraction of
the extracellular portion in the active-state KOP, with extracel-
lular loop (ECL) 2, and transmembrane helices (TMs) 4–6 moving
closer to the receptor core (Figure 2B). The orthosteric pocket of
the active-state structure shows a 10% reduced volume when
compared with that of the inactive-state KOP-JDTic complex
(945 Å3 in active KOPvs.1,049 Å3 in inactive KOP) (Figure 2D).
Similar inward movements of helices and a contraction of the
pocket were also observed in the active-state MOP structure
(Figure 2E), and other active-state GPCR structures (Figure S2F)
(Huang et al., 2015; Kruse et al., 2013; Rasmussen et al., 2011b).
These conserved structural rearrangements may indicate a
general activation mechanism among many Class A GPCRs
whereby contraction of the helical bundle on the extracellular
side facilitates an opening of the helical bundle on the intracel-
lular side which accommodates the binding of transducers
(and vice versa). The larger contraction in the KOP orthosteric
site (10%,104 Å3) compared to MOP (6%, 58 Å3) is likely
due to the more compact positions of TM2, TM3, TM6 and
Figure 1. Identification of Inactive- and Active-State-Stabilizing Nanobodies and Overall Structure of the KOP-MP1104-Nb39 Complex
(A) Cartoon of receptor-nanobody (Nb) interaction monitored by bioluminescence resonance energy transfer (BRET). Agonist-stimulated GPCR is bound by
active-state-stabilizing nanobody causing BRET signal. Nanobodies are tagged with C-terminal YFP, and GPCRs are tagged with C-terminal Rluc (Renilla
luciferase).
(B) BRET measurement of SalA-mediated nanobody recruitment at KOP. The clones Nb6 and Nb7 (half maximal effective concentration [EC50] = 341 ± 15 nM),
which have the same protein sequence, show dissociation from the receptor upon SalA stimulation, indicating that Nb6/7 is pre-bound to KOP. The BRET signal
from the KOP-Nb39 complex (EC50 = 11.3 ± 1.1 nM) increases with increasing SalA concentrations, indicating that Nb39 recognizes active-state KOP (n = 3).
(C) Top: Scheme of extended ternary complex model of GPCR activation. R, receptor; L, ligand; R*, active-state receptor; X, transducer or transducer mimetics.
Middle and Bottom: Measurement of saturation binding at KOP with or without Nb39. High-affinity binding sites increase about 6-fold for the full agonist
3H-U69,593 in the presence of Nb39 (Kd = 2.80 ± 0.06 nM; Bmax = 5,262 ± 138 fmol/mg) compared to KOP alone (Kd = 5.41 ± 0.05 nM; Bmax = 860 ± 35 fmol/mg)
(n = 3). High-affinity binding sites increase by 10% for the partial agonist 3H-diprenorphine in the presence of Nb39 (Kd = 0.26 ± 0.02 nM; Bmax = 10,315 ±
195 fmol/mg) compared to KOP alone (Kd = 0.84 ± 0.05 nM; Bmax = 9,191 ± 120 fmol/mg) (n = 3).
(D) Ligand-mediated Nb39 binding to KOP measured BRET. EC50 for Nb39 recruitment: MP1104, 0.12 ± 0.02 nM; U69,593, 3.78 ± 0.04 nM; SalA, 11.2 ± 0.8 nM
(n = 3).
(E) Overall X-ray crystal structure of the KOP-MP1104-Nb39 complex.
See also Figures S1 and S2.
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aAs defined in MolProbity.TM7 around the agonist in the active-state KOP structure, and 
the deeper pocket in the KOP inactive state, stabilized by the 
unique chemotype of JDTic.
At the intracellular surface, the KOP-MP1104-Nb39 structure 
shows outward movements of TM6 (10 Å ) and ICL2 (6.7 Å ) 
and inward movements of TM5 and TM7 by 2.2 Å and 1.3 Å , 
respectively, as compared to the inactive state (Figure 2C).These rearrangements are stabilized by several key KOP-Nb39
interactions (Figure S2G) whereby Nb39 is inserted into an intra-
cellular receptor crevice that presumably serves as a binding
pocket for key signal transducer residues. This interface is
conserved among opioid receptors (Figure S2H), explaining
why the MOP-originated Nb39 also stabilizes KOP. We also
observed a conformation of KOP that is consistent with a general
expansion of the intracellular binding site to accommodate
transducers, reminiscent of those described for G protein, ar-
restin, or nanobody-stabilized active-state structures of b2AR
(Rasmussen et al., 2011a, 2011b), M2R (Kruse et al., 2013),
rhodopsin (Kang et al., 2015), and MOP (Huang et al., 2015).
Molecular Determinants for KOP Ligand Binding and
Agonist Efficacy
Next, we characterized ligand-receptor contacts of the agonist
MP1104 and the antagonist JDTic bound to the KOP orthosteric
pocket. We found that the JDTic and MP1104 core scaffolds as-
sume distinctive poses (Figure 3A), albeit with common features
typical for opioid ligands: (1) anchored in the receptor binding
pocket through a salt bridge to D1383.32 in TM3, (2) interacting
with TM5 through a phenolic group, and (3) forming interactions
with TM2/3 via chemically diverse moieties.
The antagonist JDTic and the agonist MP1104 both form a salt
bridge between their respective amine moieties and D1383.32 of
the receptor as observed in many GPCR-ligand complexes (Fig-
ure 3A). The larger distance of this salt bridge (3.0 Å) compared to
similar interactions in the KOP-JDTic (2.6 Å), and MOP-BU-72-
Nb39 (2.7 Å) structures implies a weaker ionic interaction be-
tween MP1104 and KOP. Our mutagenesis study confirmed
that, similar to SalA which does not contain a basic amine,
MP1104 maintains high binding affinity (Figure 3B) but attenu-
ated functional activity at the D1383.32A mutant, whereas
Dynorphin A 1–17 binding and functional activity is abolished
(Vardy et al., 2015) (Table S2). D1383.32 also forms a hydrogen
bond network with T1112.56 and Y3207.43 in KOP-MP1104-
Nb39 that is likely critical for full KOP activation as mutation of
these residues strongly attenuates or abolishes b-arrestin2
recruitment mediated by MP1104 or Dynorphin A 1–17, respec-
tively (Figure S3A).
The MP1104 and JDTic phenolic groups extend toward TM5
forming water-mediated hydrogen bonds with the backbone
carbonyl oxygen of K2275.39 –as seen in other opioid receptor
structures (Fenalti et al., 2014; Huang et al., 2015; Manglik
et al., 2012; Wu et al., 2012). This interaction has been proposed
to mimic that of the N-terminal tyrosine found in endogenous
opioid peptides (Fenalti et al., 2015; O’Connor et al., 2015).
Because of the lower resolution of the KOP-MP1104-Nb39
structure, we do not observe the waters involved in this interac-
tion, but could predict their position by energy-based water
modeling algorithms. (Figure S3B). Support for this prediction
comes from studies where we replaced the hydroxyl groups
(OH) on the MP1104 scaffold with a methoxy group (OCH3),
resulting in decreased KOP affinity (Figure S3C) as observed
for similar JDTic modifications (Urbano et al., 2014). The me-
thoxy substitution, however, affects MOP binding affinity more
severely than KOP, and these findings suggest that interactions
with TM5 can be exploited for KOP selective ligand design.
Figure 2. Large-Scale Structural Changes between Inactive and Active KOP
(A) Structural alignment of active (blue) and inactive (PDB: 4DJH, gray) KOP shows TM6 outward displacement of 10 Å.
(B) Extracellular view highlights contraction of the TMs and extracellular loops upon binding to MP1104 (orange) versus JDTic (purple). Distances were measured
between Ca atoms of I581.31, Q1152.60, Q213ECL2, D2235.35, L2996.60, and S3107.33.
(C) Intracellular view shows expansion of the 7TM bundle upon binding of MP1104 and Nb39 versus JDTic, with particularly pronounced movements in TM5-7
and ICL2. Distances were measured between the Ca atoms of K2545.66, D2666.27, Y3307.53, and D168ICL2. Nb39 and T4L fusion proteins have been omitted for
clarity.
(D and E) Reduction of orthosteric site volumes in KOP and MOP upon activation. Superimposed pockets for inactive (PDB: 4DJH, gray) (1,049 Å3) and active
(blue) (945 Å3) KOP (D). Superimposed pockets for MOP, inactive (PDB: 4DKL, gray) 1,112 Å3 and active (PDB: 5C1M, green) 1,053 Å3 (E). Volumes were
calculated for the pockets of 4 superimposed receptors and uniformly delimited between the level of extracellular lipid layer boundary (as predicted by OMP
database) and the Ca atom of conserved residue W6.48.
See also Figure S2.MP1104’s cyclopropylmethyl group extends into a hydropho-
bic pocket at the bottom of the orthosteric site, similar to the iso-
propyl moiety in JDTic (Figure 3C). This hydrophobic pocket has
been proposed to play an important role in determining agonist
or antagonist activity at MOP (Huang et al., 2015). Our analysis
indicates that the connection between ligand-receptor interac-
tions within this hydrophobic pocket of opioid receptors andcorresponding ligand efficacy may not be as straightforward as
previously proposed. Compared to MP1104’s cyclopropyl-
methyl group, BU-72 in the MOP/BU-72 complex has a methyl
substituent at its tertiary amine, and thus does not fully extend
into this hydrophobic pocket (Figure 3C) (Huang et al., 2015).
We observed several contacts between MP1104 and residues
of this hydrophobic pocket including hydrophobic interactions
Figure 3. MP1104 Interactions in the Active-State KOP Binding Pocket
(A) Binding pose comparison of MP1104 (orange) in the active-state KOP (blue) compared with JDTic (purple) in the inactive state (gray, PDB: 4DJH). Main
interactions involved MP1104 and binding pocket residues are shown, with hydrogen bonds depicted as dashed lines (black).
(B) Comparison of MP1104 or SalA binding affinity at KOP WT and KOP D1383.32A mutant using 3H-diprenorphine (n = 3). See Table S2 for values.
(C) Top: Major interactions between the cyclopropylmethyl group of MP1104 (orange) and the hydrophobic pocket of active KOP (blue). Bottom: Comparison of
binding pose between MP1104 (orange) and BU-72 (green) in KOP and MOP shows that MP1104 extends into the hydrophobic pocket but BU-72 does not.
(D and E) Mutations of hydrophobic pocket residues (W2876.48L, G3197.42L, and Y3207.43L) strongly affect MP1104’s G protein activation (D) and b-arrestin2
recruitment (E), as measured by cyclic AMP (cAMP) inhibition and Tango assay, respectively (n = 3). See Tables S3 and S4 for values.
See also Figure S3.between the cyclopropylmethyl group and the aromatic ring of 
the Y3207.43 side chain, the side chain of W2876.48, and the back-
bone of G3197.42 (Figure 3C).
The Y3207.43L and G3197.42L mutations strongly reduced 
MP1104’s potency for both G protein signaling and b-arrestin2 
recruitment, while the W2876.48L mutant, selectively reducedMP1104’s b-arrestin2 recruitment potency (Figures 3D and 3E;
Tables S3 and S4). Similar effects were also observed for other
tested KOP agonists (Tables S3 and S4), suggesting that this
pocket is a general node in relating structural changes in the
binding pocket to the engagement of transducers. Importantly,
substituting MP1104’s cyclopropylmethyl with a methyl group
resulted in a >15-fold reduction of KOP agonist potency (Fig-
ure S3D). Since MP1104 potently activates all three canonical
opioid receptors (Figure S1E), we docked MP1104 into the
MOP active state and observed a similar orientation as BU-72,
with MP1104’s cyclopropylmethyl group extending into MOP’s
hydrophobic pocket (Figure S3E).
Collectively our results indicate that the precise orientation of
the rigid and bulky morphinan scaffold within the binding pocket
is critical for determining ligand efficacy/potency via minor
changes in contact forces or tensions generated by substituents.
The orientationwithin the pocket likely depends on (1) the hybrid-
ization of intramolecular bonds that determines the angles be-
tween the functional modules of the compound and (2) receptor
subtype specific interactions. Accordingly, even small modifica-
tions to identical scaffolds can subtly affect a compound’s bind-
ing mode and, thereby, its potency and/or efficacy, as observed
for other GPCR ligands (Wacker et al., 2017b).
Potential Mechanisms of KOP Activation
To clarify molecular mechanisms of KOP activation, we investi-
gated in detail how conformational changes are likely propa-
gated between ligand and transducer binding sites (Figure 4A).
Weobserved several rearrangements in theMP1104-bound or-
thosteric site, specifically in the anchoring D3.32YYNM3.36 motif
(Figure 4B), which is conserved in opioid receptors and formed
by TM3 residues that have previously been proposed as a hub
of GPCR structural rearrangements (Venkatakrishnan et al.,
2013). MP1104’s cyclopropylmethyl group interacts with the
conserved W2876.48 residue of the CWxP motif within hydropho-
bic pocket (Figure 3C), and with M1423.36 of the D3.32YYNM3.36
motif.W2876.48, which is located at the center of an aromatic clus-
ter involved inGPCRactivation (Holst et al., 2010; Shi et al., 2002),
forms hydrophobic contacts with F2836.44, thus coupling the
ligand binding site to the P5.50-I3.40-F6.44 motif, a central ‘‘micro-
switch’’ for the activation of many GPCRs (Katritch et al., 2013).
Facilitated by KOP’s ligand binding site contraction in the active
state, P2385.50 moves inward and I1463.40 changes its side chain
rotameric state, which likely promotes the rotation of F2836.44
(Figure 4C). This rotation has been linked to the TM6 swivelmotion
causing receptor opening on the intracellular side for transducer
binding (Figure 2A) (Katritch et al., 2013; Rasmussen et al.,
2011a; Valentin-Hansen et al., 2012; Wacker et al., 2013).
Changes in TM3 residues also appear to connect the orthos-
teric and sodium pocket, the NPxxY motif, and larger scale acti-
vation-related changes in TM7. The sodium pocket is located
between TM2, TM3 and TM7 and accommodates a single so-
dium ion, which acts as a negative allosteric modulator at opioid
receptors (Fenalti et al., 2014; Pasternak et al., 1975; Pert et al.,
1973) and most other GPCRs (Katritch et al., 2014). In KOP,
D1052.50, N1413.35 and S1453.39 form the sodium pocket, which
collapses upon activation and instead D1052.50 forms a
hydrogen bond with S1453.39 (Figure 4D). The N1413.35 side
chain changes its rotameric state in the active state of KOP (Fig-
ure 4D) similar toMOP (Huang et al., 2015), and directly connects
changes in the orthosteric site to the sodium pocket. As in DOP
(Fenalti et al., 2014), N3.35 forms a water-mediated hydrogen
bond with D3.32 and directly coordinates sodium. Through a
hydrogen bond between D1052.50 and N3267.49, the sodiumpocket is further directly coupled to the NPxxY motif at the intra-
cellular tip of TM7, which has been implicated in propagating
structural changes in the orthosteric site through a sequence
of conformational changes leading to larger scale helical move-
ments (Katritch et al., 2014; Valentin-Hansen et al., 2012).
Furthermore, upon KOP activation, the NPxxY motif residues
N3227.45 and Y3307.53 move toward the receptor core by 1.7 Å
and 3.9 Å, respectively, with the hydroxyl group of Y3307.53 mov-
ing as much as 7.8 Å (Figure 4E), which is consistent with similar
activation-related changes in other class A GPCRs (Katritch
et al., 2013).
At the intracellular end of TM3, we observed additional struc-
tural rearrangements in the conserved DRY motif, which has
been shown to directly interact with signal transducers through
R1563.50. Specifically, we observed that the salt bridge between
R1563.50 and D1553.49, which is characteristic for many inactive-
state structures, is broken in the KOP active state, and instead
R1563.50 points toward the receptor core, forming a hydrogen-
bond with Y2465.58 (Figure 4F). A similar configuration of R3.50
has previously been observed in the structures of b2AR bound
to a heterotrimeric G protein (Rasmussen et al., 2011b), adeno-
sine A2A receptor bound to a thermostabilized ‘‘mini-Gs’’ (Car-
penter et al., 2016), opsin bound to a C-terminal peptide of
transducin (Scheerer et al., 2008), and rhodopsin bound to visual
arrestin (Kang et al., 2015).
Together, our observations confirm and extend previous sug-
gestions that structural changes in TM3 residue interfaces are
critical for coupling ligand-mediated changes in the orthosteric
site and the transducer interface (Venkatakrishnan et al., 2013).
This hypothesis is further strengthened by the finding that an
N1413.35A mutation converts several antagonists into full ago-
nists (Figure 4G).
Structural Determinants for Biased Signaling and
Subtype Selectivity
Pathway selective KOP ligands are not only important tools
for elucidating receptor mechanisms and uncovering novel re-
ceptor physiology, they are also therapeutically desirable. It is
becoming clear that KOP’s analgesic and anti-pruritic effects
appear to be G protein mediated, while many of the undesirable
actions of KOP agonists may be mediated by arrestin-ergic and
other non-canonical pathways (Bruchas and Roth, 2016; Brust
et al., 2016; White et al., 2015). We thus performed structure-
activity relationship (SAR) and docking experiments to identify
and further characterize the molecular determinants for biased
signaling at KOP.
Clues regarding the structural features responsible for biased
signaling at KOP come from studying IBNtxA (Majumdar et al.,
2011), a close MP1104 analog. Compared to MP1104, IBNtxA
has a substituted hydroxyl group at position C14 and a fully satu-
rated cyclohexanyl C-ring (Figure 5A). Although MP1104 is a full
and unbiased agonist at both KOP and MOP, IBNtxA displays
G protein signaling bias at MOP (Figures 5B, 5C, and S4A; Table
S5). To understand themolecular basis of these functional differ-
ences, we docked IBNtxA into the active-state structures of KOP
and MOP. We observed substantial conformational differences
within the orientation of the iodobenzamide moiety of the com-
pound (Figure S4B) likely due to MP1104’s boat configuration
Figure 4. Activation Signal Propagation within KOP Motifs
(A) Close-ups highlight activation-related conformational changes in key receptor motifs and show connection of structural changes from orthosteric site to the
cytoplasmic transducer binding site.
(B–F) Conformational changes between active KOP (blue) and inactive KOP (gray) are highlighted for MP1104 binding pocket (B), P-I-F motif (C), sodium binding
pocket (D), NPxxY motif (E), and DRY motif (F).
(G) KOP N1413.35A mutation switches classic opioid receptor antagonists (left) into full agonists (right) in Tango-arrestin recruitment (n = 3). KOP WT: MP1104
(red), EC50 = 0.071 ± 0.008 nM, Emax = 100 ± 2; KOP N141
3.35A: MP1104 (red), EC50 = 0.027 ± 0.008 nM, Emax = 100 ± 2, naltrexone (orange), EC50 = 6.53 ±
0.90 nM, Emax = 107 ± 3, naloxone (light green), EC50 = 12.75 ± 1.50 nM, Emax = 93 ± 2, 6b-naltrexol (green), EC50 = 22.47 ± 1.8 nM, Emax = 120 ± 2.and IBNtxA’s chair configuration, caused by their respective 
unsaturated and saturated C-rings (Figure 5A). IBNtxA’s iodo-
benzamide moiety is pointed toward the extracellular region in 
both receptors, instead of toward TM2 and TM3 as for MP1104. 
In KOP, MP1104’s iodobenzamide moiety appears sta-bilized by 
a weak, water-mediated hydrogen bond between the ligand’s 
carbonyl and Y3127.35 (3.6 and 4.1 Å distance in mole-cules A 
and B respectively), while MOP contains W3207.35 atthis position (Figure 5A). Since the IBNtxA docking pose in
KOP suggests a similar receptor interaction through a stronger
direct or water-mediated bond to Y3127.35 (3.4 Å distance) (Fig-
ure 5A), we hypothesized that differences at position 7.35 could
explain IBNtxA’s functional dissimilarities between MOP and
KOP. Indeed, when we mutated KOP’s Y3127.35 to a tryptophan
tomimicMOP’s configuration, we observed a pathway-selective
attenuation of IBNtxA’s arrestin recruitment potency, while
Figure 5. Structural Insights for the Design of Biased and Selective KOP Ligands
(A) Chemical structures of MP1104 and IBNtxA. Chemical differences are highlighted by color. Comparison of iodobenzamide binding pose between MP1104
(orange, top) and docked IBNtxA (white, bottom) in KOP (blue). Y3127.35 in KOP forms a hydrogen bond with amide oxygen of both compounds.
(B)MP1104 (red) and IBNtxA (orange) are balanced full agonists in KOPmeasuring in cAMP inhibition and Tango-arrestin recruitment. Gi: MP1104, EC50 = 0.003 ±
0.001 nM, Emax = 97 ± 1; IBNtxA, EC50 = 0.002 ± 0.001 nM, Emax = 96 ± 1. Arrestin: MP1104, EC50 = 0.035 ± 0.010 nM, Emax = 115 ± 8; IBNtxA, EC50 = 0.032 ±
0.010 nM, Emax = 113 ± 12. Bias factor toward G protein: 0.6 and 1.5 for MP1104 and IBNtxA, respectively (n = 3).
(C) IBNtxA (orange) displays G-protein-biased activity in MOP, whereas MP1104 (red) appears balanced in cAMP inhibition and Tango-arrestin recruitment. Gi:
MP1104, EC50 = 0.04 ± 0.010 nM, Emax = 103 ± 6; IBNtxA, EC50 = 0.056 ± 0.012 nM, Emax = 99 ± 6. Arrestin: MP1104, EC50 = 0.55 ± 0.03 nM, Emax = 126 ± 7;
IBNtxA, EC50 = 0.10 ± 0.03 nM, Emax = 23 ± 4. Bias factor toward G protein: 1.6 and 12 for MP1104 and IBNtxA, respectively (n = 3).
(D) The KOP Y3127.35W mutant (orange) shows slightly reduced MP1104-mediated arrestin recruitment and strongly reduced IBNtxA-mediated arrestin
recruitment compared to KOP WT (red) (n = 3). MP1104/KOP WT: EC50 = 0.035 ± 0.010 nM, Emax = 119 ± 9; MP1104/KOP Y312
7.35W: EC50 = 0.055 ± 0.02 nM,
Emax = 111 ± 4. IBNtxA/KOP WT: EC50 = 0.03 ± 0.01 nM, Emax = 112 ± 10; IBNtxA/KOP Y312
7.35W: EC50 = 0.20 ± 0.06 nM, Emax = 52 ± 4.
(E) Binding affinity of nalfurafine (Ki = 0.32 ± 0.02 nM in KOP and 4.20 ± 0.21 nM in MOP) and compound 18 (Ki = 1.50 ± 0.05 nM in KOP and 533 ± 65 nM in MOP)
(n = 3).
See also Figures S4 and S5.MP1104 was only slightly affected (Figure 5D). Moreover, we
observe similar functional profiles for several analogs that all
contain saturated C-rings (Figure S4C).In addition to the desired signaling properties, subtype selec-
tivity is critical for developing safer therapeutics with reduced
side effects. To identify features responsible for selective KOP
actions, we next docked representative agonists U69,593, 
U50,488, and SalA into the current active-state structure. 
U69,593 and U50,488 (Figure S5A) show similar binding poses, 
forming ionic interactions between the pyrrolidinyl/amide 
nitrogen and D1383.32, while exhibiting steric overlap with 
the MP1104 crystallographic pose. One major difference of 
U69,593 or U50,488 from peptides and morphinan opioids is 
the lack of phenol moiety, which interacts with H2916.52 and 
Y1393.33 residues in the classical opioids. Accordingly, muta-
tions in these residues to Ala had no significant impact on ligand 
binding to U69,593, while Dynorphin A binding was reduced 
by >10-fold and 5-fold, respectively (Vardy et al., 2013). At 
the opposite side of the pocket, the phenyl ring of both 
U69,593 and U50,488 occupies the same pocket as the iodo-
phenyl moiety in the MP1104-KOP structure and the linker amide 
of both also forms a hydrogen bond with Q1152.60. SalA’s dock-
ing mode (Figure S5B) is consistent with previous studies (Cun-
ningham et al., 2011; Vardy et al., 2013; Wu et al., 2012; Yan 
et al., 2009). In our current model, Y3127.35 forms a hydrogen 
bond with the carbonyl oxygen atom of SalA at the 1-position 
(see Figure S5B for atom numbering). The SalA 2-position acetyl 
group forms hydrophobic interactions with the aromatic ring 
of Y3127.35 and may hydrogen bond with the neighboring 
Y3137.36 hydroxyl group. The 4-position methyl ester of SalA is 
situated in a small, largely enclosed pocket where it is stabilized 
by an H-bond with the C210ECL2 backbone NH group. The furan 
ring of SalA engages in edge-face aromatic interactions with 
Y1393.33. It is noteworthy that these docking poses based on 
the active-state KOP structure are somewhat different from 
those derived from the inactive-state KOP-JDTic structure 
(Vardy et al., 2013), highlighting the unique conformation of the 
active-state binding pocket.
Efforts to improve KOP selectivity by modifying MP1104’s or 
IBNtxA’s iodobenzamide group were unsuccessful (Figure S5C). 
Instead, we adopted a novel strategy which emerged from our 
earlier structure-guided observation that modifications of the 
morphinan phenolic group affects binding affinity for KOP less 
than for MOP (Figure S3C).
The ligands’ phenol groups interact with a complex water 
network that is different between opioid receptor subtypes due 
to non-conserved residues in positions 5.36, 6.58, and 7.35, 
which form part of the ‘‘address’’ domain in opioid receptors 
(Larson et al., 2000) (Figure S3B). In MOP, the phenolic group 
of BU-72 forms strong water-mediated interactions with the 
side chain of K3036.58 (Huang et al., 2015). In contrast, in KOP 
the shorter E2976.58 side chain precludes formation of this 
water-mediated interaction with MP1104’s phenolic group. 
This suggests that removal of the phenolic moiety can differen-
tially reduce MOP ligand affinity without impacting KOP binding. 
As mentioned above, the KOP-selective agonists U69,593 and 
U50,488 lack the phenolic group. Moreover, comparison of 
Nalfurafine, an approved IBNtxA-related analog for chronic itch 
(Endoh et al., 2001), and its analog compound 18, which lacks 
the hydroxyl moiety of the phenolic group (Nagase et al., 2012)
(Figure 5E), revealed a large reduction in MOP affinity, while re-
taining high KOP affinity (Figure 5E). Thus, modification of the 
phenol group represents a viable path toward generating KOP 
selective ligands with improved pharmacological profiles.DISCUSSION
Here, we present the nanobody-stabilized active-state structure
of KOP and provide detailed molecular insights into KOP activa-
tion, opioid receptor selectivity, and biased signaling.
While we observed large-scale conformational changes in the
KOP active state reminiscent of those seen in other GPCRs, we
also find distinct rearrangements in the KOP’s ligand binding
pocket. A detailed analysis of these differences highlights limita-
tions of prior ‘‘message-address’’-based hypotheses (Larson
et al., 2000), which postulated that opioid receptor selectivity
and efficacy are determined by distinctive compound moieties.
Previous studies suggested that larger hydrophobic amine sub-
stituents on prototype morphinans conferred opioid antagonism
and thereby provided a roadmap for the design of selective
agonists and antagonists. Instead, our findings indicate that
combinatorial interactions with conserved and non-conserved
residues specify ligand selectivity, pharmacology, efficacy and
signaling bias.
Using a combination of structural analysis, molecular docking,
binding, and functional studies, we identified important opioid
receptor residues involved in conferring different patterns
of biased signaling between opioid receptor subtypes. For
instance, we showed that replacing Y7.35 in the binding pocket
of KOP with W7.35 found in MOP, transforms the balanced
KOP agonist IBNtxA into a G-protein-biased ligand thereby
mimicking its activity at MOP. The finding that residues at the
same position confer differential signaling patterns is consistent
with observations that a ligand may elicit very different patterns
of activity between two receptors. Molecular insights into these
mechanisms ultimately may be exploited for the design of poly-
pharmacological ligands with ‘‘customized’’ activities at each
target.
Taken together, these findings not only expand our general
mechanistic framework of GPCR activation but also provide mo-
lecular insights into KOP structure and function. Given the urgent
need to develop safer opioidmedications in an effort to battle the
growing opioid epidemic, these molecular insights could greatly
accelerate the design of novel KOP ligands through structure-
enabled technologies and large-scale virtual ligand screening.STAR+METHODS
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EXPERIMENTAL MODEL AND SUBJECT DETAILS
For KOP expression, we used the Sf9 insect cells derived from the parental Spodoptera frugiperda cell line IPLB-Sf-21-AE (Expres-
sion systems). Cells were grown in ESF 921medium (Expression systems) at 27C and 125 rpm. Nanobodies were expressed at 27C
in E. coli WK6 (su-) cells in TB medium (Terrific Broth, Sigma). Nanobodies were induced with 1 mM IPTG (final concentration,
Isopropyl b-D-1-thiogalactopyranoside) when the bacteria density reached an OD600 of 0.6-0.8 and bacteria cells were grown over-
night at 170 rpm. For KOP functional assays, Human embryonic kidney (HEK) 293T (ATCC CRL-11268) cells were cultured in DMEM
(Dulbecco’sModified EagleMedium). Wild-type ormutant KOP plasmids were transfected into HEK293T cells using the calcium pre-
cipitation method.
METHOD DETAILS
Generation of human KOP receptor crystallization construct
Crystallization of the human KOP complex was done using an engineered receptor construct that was modified based on the
KOP-T4L sequence (Wu et al., 2012). The final construct a) lacks N-terminal residues 1-53, b) lacks C-terminal residues 359-380,
c) contains M1-L106 of the thermostabilized apocytochrome b562 RIL (BRIL) from E. coli (M7W, H102I, R106L) in place of receptor
N terminus residues M1-H53, a glycine-serine linker was inserted between BRIL and receptor to facilitate crystallization. Further
modifications are I135L mutation was introduced to increase expression; a haemagglutinin (HA) signal sequence followed by a
FLAG tag at the N terminus, then a 10X His tag followed by a TEV protease site to enable purification by immobilized metal affinity
chromatography.
Discovery and purification of nanobodies
KOP specific nanobodies were generated as described before (Pardon et al., 2014). In brief, one llama (Lama glama) was immunized
six times with in total 0.5 mg purified BRIL-KOP DREADD (KOP D1383.32N) bound to SalA [KOP D1383.32N was used here because it
has higher affinity with SalA than wild-type (Vardy et al., 2015)]. Four days after the final boost, blood was taken to isolate peripheral
blood lymphocytes. RNA was purified from these lymphocytes and reverse transcribed by PCR to obtain cDNA. The resulting library 
was cloned into the phage display vector pMESy4 bearing a C-terminal hexa-His tag and a Glu-Pro-Glu-Ala-tag (EPEA-tag, also 
called or CaptureSelect C-tag). Selections were performed either on BRIL-KOP in liposomes solid phase coated directly on plates. 
Six different families were selected by biopanning. After two rounds of selection, periplasmic extracts were made and subjected to 
ELISA screens. Clones giving a positive signal in ELISA were sequenced and analyzed. Plasmids were transformed to E. coli WK6 
cells, KOP specific nanobodies i.e., Nb6 and Nb7 were expressed and purified following steps 70-73 described in the previous pro-
tocol (Pardon et al., 2014). Nb39 DNA sequence was synthesized (Integrated DNA Technologies, IDT) based on the protein sequence 
in the active-state MOP structure (PDB: 5C1M) (Huang et al., 2015), and was expressed and purified using the same protocols as 
Nb6/7. Nanobodies were concentrated and desalted to the buffer: 10 mM HEPES, 100 mM NaCl and 10% Glycerol and stored 
at 80C for future use.
Expression and purification of KOP
High-titer recombinant baculovirus (> 109 viral particles per ml) was generated using the Bac-to-Bac Baculovirus Expression System 
(Invitrogen). 5 mg of recombinant bacmid in 50 ml Sf-900 II SFM media (Invitrogen) and 3 ml Cellfectin II Reagent (Invitrogen) in 
another 50 ml Sf-900 II SFM media (Invitrogen) were incubated for 30 min. Recombinant baculovirus was obtained by transfecting 
the above mixed solution into 400 ml Sf-900 II SFM media including 5x105 settled Spodoptera frugiperda (Sf9) cells (Expression Sys-
tems) in a 12-well plate (Corning). After 5 h, media was exchanged for 1 mL Sf-900 II SFM media (Invitrogen) and incubated for 5 days 
at 27C. P0 viral stock with 109 virus particles per ml was harvested as the supernatant and used to generate high-titer baculovirus 
stock by infection of 40 mL of Sf9 cells (cell density: 2-3 3 106 cells/ml) and incubation for 3 days. Viral titers were determined by flow-
cytometric analysis of cells stained with gp64-PE antibody (Expression Systems). Expression of KOP was carried out by infection of 
Sf9 cells at a cell density of 2.5 3 106 cells/ml in ESF921 media (Expression Systems) with P1 or P2 virus at a MOI (multiplicity of 
infection) of 3. 5% production boost additive (PBA, Expression Systems) was added to maintain cell alive. Final concentration 
of 10 mM naltrexone was added to help the receptor trafficking. Cells were harvested by centrifugation at 48 h post infection, washed 
in 1x PBS, and stored at 80C until use. Cells were first washed by resuspending frozen cell pellets in a low-salt buffer containing 
10 mM HEPES, pH 7.5, 10 mM MgCl2, 20 mM KCl and protease inhibitors (500 mM AEBSF, 1 mM E-64, 1 mM Leupeptin, 150 nM Apro-
tinin). Membranes purification was followed by 4 repeated centrifugation in a high osmolarity buffer containing 1.0 M NaCl, 10 mM 
HEPES, pH 7.5, 10 mM MgCl2, 20 mM KCl, to remove soluble and membrane associated proteins. Purified membranes were directly 
flash-frozen in liquid nitrogen and stored at 80C for future use.
Purified membranes were resuspended in buffer containing 10 mM HEPES, pH 7.5, 10 mM MgCl2, 20 mM KCl, 150 mM NaCl, 
50 mM MP1104 (synthesized in house), and 1x protease inhibitors (500 mM AEBSF, 1 mM E-64, 1 mM Leupeptin, 150 nM Aprotinin), 
and incubated at room temperature for 1 h. The sample was then transferred to 4C for 30 min. After another 30 min incubation in the 
presence of 2 mg/ml iodoacetamide (Sigma), membranes were solubilized in 10 mM HEPES, pH 7.5, 150 mM NaCl, 1% (w/v) 
n-dodecyl-b-D-maltopyranoside (DDM, Anatrace), 0.2% (w/v) cholesteryl hemisuccinate (CHS, Sigma), and protease inhibitors for 
2 h at 4C. The supernatant was obtained by centrifugation at 150,000 3 g for 30 min and was incubated with 20 mM imidazole 
and TALON IMAC resin (Clontech) overnight at 4C using approximately 500 ml resin for protein purified from 1 L of cells. The resin 
was then washed with 10 column volumes (cv) of Wash Buffer I (50 mM HEPES, pH 7.5, 800 mM NaCl, 0.1% (w/v) DDM, 0.02% (w/v) 
CHS, 20 mM imidazole, 10% (v/v) glycerol, and 25 mM MP1104, followed by 10 cv of Wash Buffer II (25 mM HEPES, pH 7.5, 150 mM 
NaCl, 0.05% (w/v) DDM, 0.01% (w/v) CHS, 10% (v/v) glycerol, and 25 mM MP1104). Proteins were eluted in 2.5 cv of Wash Buffer II + 
250 mM imidazole, concentrated in a 100 kDa molecular weight cut-off Vivaspin 20 concentrator (Sartorius Stedim) to 500 ml, and 
imidazole was removed by desalting the protein over PD MiniTrap G-25 columns (GE Healthcare). The N-terminal 10 3 His-tag 
was removed by addition of His-tagged TEV protease (Homemade) and incubation overnight at 4C. Protease, cleaved His-tag 
and uncleaved protein were removed by passing the suspension through equilibrated TALON IMAC resin (Clontech) and collecting 
the flow-through. Excessive Nb39 (KOP/Nb39 m/m: 1:2) was then added to the protein sample and incubated for 3 h. KOP-MP1104-
Nb39 complexes were then concentrated to 30 mg/ml with a 100 kDa molecular weight cut-off Vivaspin 500 centrifuge concentrator 
(Sartorius Stedim). Protein purity and monodispersity were tested by analytical size-exclusion chromatography.
Lipidic cubic phase crystallization
KOP-MP1104-Nb39 complexes were reconstituted into lipidic cubic phase (LCP) by mixing protein solution and a monoolein/choles-
terol (10:1 w/w) mixture in a ratio of 2:3 v/v (protein solution/lipid) using the twin-syringe method (Caffrey and Cherezov, 2009). Crys-
tallization was set up in 96-well glass sandwich plates (Marienfeld GmbH) using 50 nL LCP drops dispensed from a 10 mL gas-tight 
syringe (Hamilton) using a handheld dispenser (Art Robbins Instruments) and overlaid with 1 ml of precipitant solution. Upon optimi-
zation, KOP-MP1104-Nb39 crystals were obtained in 100 mM Bis-tris pH 6.5-7.0, 140-200 mM magnesium sulfate hydrate, 100 mM 
sodium citrate tribasic dehydrate, 10 mM Manganese(II) chloride tetrahydrate, 28%–30% PEG400. Crystals grew to a maximum size 
of 50 mm 3 30 mm 3 20 mm within three days and were harvested directly from the LCP matrix using MiTeGen micromounts before 
flash-freezing and storage in liquid nitrogen.
Data collection, structure solution and refinement
X-ray data were collected at the 23ID-B and 23ID-D beamline (GM/CA CAT) at the Advanced Photon Source, Argonne, IL using a
10 mm minibeam at a wavelength of 1.0330 Å and a Dectris Eiger-16 m detector and Dectris Pilatus3-6 m detector, respectively.
Diffraction datawere collected by exposing the crystals for 0.2 s to an unattenuated beamusing 0.2 oscillation per frame. 315 frames
collected from 21 crystals were indexed, integrated, scaled, and merged using HKL3000 (Minor et al., 2006). Initial phases were ob-
tained by molecular replacement in PHASER (McCoy et al., 2007) using 3 independent models of a truncated 7TM portion of KOP
(PDB ID: 4DJH), a nanobody Nb39 from the MOP-Nb39-BU-72 complex (PDB ID: 5C1M), and the thermostabilized apocytochrome
b562RIL protein (PDB ID: 1M6T) (Chu et al., 2002). Two copies of the 7TM portion of each the receptor and the nanobody Nb39 but no
BRIL were found in asymmetric unit. Refinement was performed with PHENIX (Adams et al., 2010), REFMAC5 (Murshudov et al.,
1997) and autoBUSTER (Smart et al., 2012) followed by manual examination and rebuilding of the refined coordinates in the program
COOT (Emsley et al., 2010) using 2mFo - DFc and mFo - DFc maps. Final refinement was performed using autoBUSTER with four TLS
groups (two KOP and two Nb39 TLS groups), a total of 882 residues (307 KOP and 134 Nb39), and two MP1104 ligands and two
cholesterols molecules. The data collection and refinement statistics are shown in Table 1.
cAMP inhibition assay.
To measure KOP Gai-mediated cAMP inhibition, HEK293T (ATCC CRL-11268) cells were co-transfected with human KOP along
with a luciferase-based cAMP biosensor (GloSensor; Promega) and assays were performed similar to previously described (Fenalti
et al., 2014). After 16 h, transfected cells were plated into Poly-lysine coated 384-well white clear bottom cell culture plates with
DMEM + 1% dialysed FBS at a density of 15,000-20,000 cells per 40 mL per well and incubated at 37C with 5% CO2 overnight.
The next day, drug solutions were prepared in fresh drug buffer [20 mM HEPES, 1X HBSS, 0.3% bovine serum album (BSA),
pH 7.4] at 3X drug concentration. Plates were decanted and received 20 mL per well of drug buffer (20mMHEPES, 1XHBSS) followed
by addition of 10 mL of drug solution (3 wells per condition) for 15 min in the dark at room temperature. To stimulate endogenous
cAMP via b adrenergic-Gs activation, 10 mL luciferin (4 mM final concentration) supplemented with isoproterenol (400 nM final con-
centration) were added per well. Cells were again incubated in the dark at room temperature for 15 min, and luminescence intensity
was quantified using a Wallac TriLux microbeta (Perkin Elmer) luminescence counter. Results (relative luminescence units) were
plotted as a function of drug concentration, normalized to % SalA stimulation, and analyzed using ‘‘log(agonist) vs. response’’ in
GraphPad Prism 5.0.
Tango arrestin recruitment assay
The KOP Tango constructs were designed and assays were performed as previously described (Kroeze et al., 2015; Liu et al., 2013).
HTLA cells expressing TEV fused-b-Arrestin2 (kindly provided by Dr. Richard Axel, Columbia Univ.) were transfected with the KOP
Tango construct. The next day, cells were plated in DMEM supplemented with 1% dialyzed FBS in poly-L-lysine coated 384-well
white clear bottom cell culture plates at a density of 10,000-15,000 cells/well in a total of 40 ml. The cells were incubated for at least
6 h before receiving drug stimulation. Drug solutions were prepared in drug buffer (20mMHEPES, 1X HBSS, 0.3%BSA, pH 7.4) at 3X
and added to cells (20 ml per well) for overnight incubation. Drug solutions used for the Tango assaywere exactly the same as used for
the cAMP assay. The next day, media and drug solutions were removed and 20 ml per well of BrightGlo reagent (purchased from
Promega, after 1:20 dilution) was added. The plate was incubated for 20 min at room temperature in the dark before being counted
using a luminescence counter. Results (relative luminescence units) were plotted as a function of drug concentration, normalized
to % SalA stimulation, and analyzed using ‘‘log(agonist) vs. response’’ in GraphPad Prism 5.0.
GTPg[35S] assay
KOP-Gai1, KOP-Gai1 Y3127.35W and MOP-Gai1 fusion constructs were transfected into HEK293T cells and membrane was pre-
pared 48 hr later. The GTPg[35S] assay was conducted in assay buffer (20 mM HEPES, 100 mM NaCl, 10 mM MgCl2, 1 mM
EDTA, 1 mM DTT, pH 7.4). In a 96-well plate, 20 mL of 30 mM GDP, 20 mL of 100 mM GTPgS (for Non-specific) or buffer (for Total),
20 mL of 3 nM GTPg[35S], 20 mL of a serial dilution of KOP agonist and 120 mL of premixed membrane and 2.1mg/mL WGA-SPA
PVT beads (Perkin Elmer) were added sequentially to each well (200 mL/well). The plate was sealed and agitated for 20-120 min
at RT, and counted in SPAmode in a TriLuxmicrobeta (Perkin Elmer). Results (CPM) were plotted as a function of drug concentration,
normalized to % SalA or DAMGO stimulation, and analyzed using ‘‘log(agonist) vs. response’’ in GraphPad Prism 5.0.
Bioluminescence Resonance Energy Transfer (BRET) assay
To measure KOP-nanobody recruitment, HEK293T cells were co-transfected in a 1:3 ratio with human KOP containing C-terminal
Renilla luciferase (RLuc8) and nanobody containing a C-terminal YFP (with or without indicated concentrations of unlabeled Gai1
or b-arrestin2). After at least 16 hours, transfected cells were plated in poly-lysine coated 96-well white clear bottom cell culture
plates in plating media (DMEM + 1% dialyzed FBS) at a density of 40-50,000 cells in 200 ml per well and incubated overnight. The
next day, media was decanted and cells were washed twice with 60 mL of drug buffer (20 mM HEPES, 1X HBSS, pH 7.4), then
60 mL of the RLuc substrate, coelenterazine h (Promega, 5 mM final concentration in drug buffer) was added per well, incubated
an additional 5 minutes to allow for substrate diffusion. Afterward, 30 mL of drug (3X) in drug buffer (20 mM HEPES, 1X HBSS,
0.1% BSA, pH 7.4) was added per well and incubated for another 5 minutes. Plates were immediately read for both luminescence
at 485 nm and fluorescent eYFP emission at 530 nm for 1 s per well using a Mithras LB940 multimode microplate reader. The ratio of 
eYFP/RLuc was calculated per well and the net BRET ratio was calculated by subtracting the eYFP/RLuc per well from the eYFP/
RLuc ratio in wells without nanobody-YFP present. The net BRET ratio was plotted as a function of drug concentration using Graph-
pad Prism 5 (Graphpad Software Inc., San Diego, CA).
Radioligand binding and ligand dissociation assays
Binding assays were performed using Sf9 membrane fractions expressing the crystallization construct BRIL-KOP or HEK293 T 
membrane preparations transiently expressing KOP wt or KOP mutants. Binding assays were set up in 96-well plates in the standard 
binding buffer (50 mM Tris, 0.1 mM EDTA, 10 mM MgCl2, 0.1% BSA, pH 7.40). Saturation binding assays with 0.1–20 nM [3H]-Dipre-
norphine or [3H]-U69,593 in standard binding buffer were performed to the determine equilibrium dissociation constant (Kd) and 
Bmax, whereas 10 uM final concentration of JDTic was used to define nonspecific binding. For the competition binding, 50 mL 
each of 3H-Diprenorphine (final 1 nM), drug solution (3X) and homogeneous membrane solution was incubated in 96-well plate in 
the standard binding buffer. Reactions (either saturation or competition binding) were incubated for 2 h at room temperature in 
the dark, and terminated by rapid vacuum filtration onto chilled 0.3% PEI-soaked GF/A filters followed by three quick washes 
with cold washing buffer (50 mM Tris HCl, pH 7.40) and read. Results (with or without normalization) were analyzed using GraphPad 
Prism 5.0 using one-site or allosteric IC50 shift models where indicated.
Radioligand dissociation assays were performed in 96-well plates in the standard binding buffer (50 mM Tris, 0.1 mM EDTA, 10 mM 
MgCl2, 0.1% BSA, pH 7.40). All assays utilized 2 concentrations of radioligand ([3H]-U69,593 = 0.5-2.0 nM) (PerkinElmer). For disso-
ciation assays, membranes were incubated with radioligand for at least 2 hours at 37C in the absence or presence of Nb6 or Nb39 
before the addition of 10 mL of 10  mM excess cold ligand to the 200 mL membrane suspension at designated time points. Time points 
spanned 2 minutes to 2 hours. Non-specific binding was determined by addition of 10 mM JDTic for KOP. Immediately at time = 0 min, 
plates were harvested by vacuum filtration onto 0.3% polyethyleneimine pre-soaked 96-well filter mats (Perkin Elmer) using a 96-well 
Filtermate harvester, followed by three washes of cold wash buffer (50 mM Tris pH 7.4). Scintillation (Meltilex) cocktail (Perkin Elmer) 
was melted onto dried filters and radioactivity was counted using a Wallac Trilux MicroBeta counter (PerkinElmer). Data were 
analyzed using ‘‘Dissociation – One phase exponential decay’’ in Graphpad Prism 5.0.
Molecular modeling
The structure of kappa opioid receptor complex co-crystallized with MP1104 was prepared for docking experiments by addition and 
optimization of hydrogen atoms, and optimization of side chain residues. The ligand docking box for potential grid docking was 
defined as the whole extracellular half of the protein, including co-crystallized MP1104 ligand. Energy minimized structures of 
MP1104, IBNtxA, U-69,593, U-50,488 and Salvinorin A (SalA) were docked unto the kappa opioid receptor orthosteric site with a 
thoroughness value of 30, and top scored docking solutions were retained. The retained top scored docking poses were further opti-
mized by several rounds of minimization and Monte Carlo sampling of ligand conformation and surrounding side chain residues 
(within 4 Å if the ligand) in the orthosteric ligand pocket. All the above molecular modeling operations were performed in ICM-Pro 
v3.8-5 molecular modeling package (Abagyan et al., 1994).
For SalA, an additional round of simulations was performed by molecular dynamics (MD) methods. Gromacs 5.0.4 (Van Der Spoel 
et al., 2005) was used to perform all MD simulations. All input files for MD simulation of the docked conformation of SalA and kappa 
opioid receptor complex, and parameter files for SalA were generated using CHARMM-GUI server (Kim et al., 2017; Lee et al., 2016). 
The orientation of helices within the membrane was derived after overlapping the complex with orientation of 4DJH (the JDTic co-
crystallized kappa opioid receptor structure) obtained from the OPM server (Lomize et al., 2006). Two MD runs of membrane 
embedded and water boxed SalA-kappa opioid receptor complex (including 218 POPC lipid molecules, 19206 water molecules, 
56 sodium ions and 61 chloride ions) were simulated with the CHARMM forcefield (Best et al., 2012) at 310K temperature with a 
step size of 2 femtoseconds using 6 GPU-enabled nodes with 16 processors for a period of 650 ns and 500 ns, after minimization 
and equilibrations. During the MD runs the hydrogen atoms were constrained using LINCS and cut-off of 12 Å was used for Van 
der Waals and short range electrostatic interactions, along with PME conditions. MD-derived receptor–ligand complexes were 
then subjected to an iterative refinement process guided by experimental data from mutagenesis studies and SalA structure–activity 
relationships (SAR). In the first step, rotatable bonds of the ligand and/or amino acid side chains of KOP were modified either manu-
ally (for the ligand) or algorithmically with a rotamer library using SCWRL4 (Krivov et al., 2009) (for KOP) so as to maximize the stereo-
electronic complementarity of the interacting partners. An energy minimization step was then performed on the complex in SYBYL-X 
2.1.1 (Certara USA, Inc., Princeton, NJ) using the Tripos Force Field (GasteigerHü ckel charges, distance-dependent dielectric con-
stant = 4.0 D/Å , termination criteria: energy gradient cut-off = 0.05 kcal (mol 3 Å )1 or 100,000 iterations). This was followed by a HINT 
(Eugene Kellogg and Abraham, 2000) analysis to assess the energetic favorability of the receptor–ligand complex. The iterative 
refinement process terminated when no further energetically favorable structural modifications could be identified. The stereochem-
ical quality of the final models was assessed using PROCHECK (Laskowski et al., 1993).
MP1104 analog synthesis
Chemicals were purchased from Sigma-Aldrich Chemicals, Fisher scientific, Alfa Aesar, and were used without further purification. 
Reaction mixtures were purified by silica gel flash chromatography on E. Merck 230–400 mesh silica gel 60 using a Teledyne ISCO
CombiFlash Rf instrument with UV detection at 280 and 254 nm. RediSep Rf silica gel normal phase columns were used with a
gradient range of 0%–10% MeOH in DCM. The yields reported are isolated yields. NMR spectra were recorded on Bruker Avance
III 600 with DCH CryoProbe instruments. Chemical shifts are reported in parts per million (ppm) relative to residual solvent peaks at
the nearest 0.01 for proton and 0.01 for carbon (CDCl3
1H: 7.26, 13C: 77.10). Peak multiplicity is reported as the NMR spectra were
processed with MestReNova software, namely s – singlet, d – doublet, t – triplet, q – quartet, m – multiplet for examples. Coupling
constant (J) values are expressed in Hz. Mass spectra were obtained at the MSKCC Analytical Core Facility using The Waters Acuity
SQD LC MS by electrospray (ESI) ionization. High resolution mass spectra were obtained on a Waters Acuity Premiere XE TOF LC-
MS by electrospray ionization. Accurate masses are reported for the molecular ion [M+H]+. Purity of the products (R95%) was
confirmed by Waters Acquity UPLC: equipped with a binary solvent manager system, Waters XBridge C18 column (1.7 mm x
2.1 3 100mm), PDA, ELS and QDa mass detectors; mobile phase: solvent A: water with 0.1% TFA; solvent B: acetonitrile with
0.1% TFA. Gradient: 5%–95% acetonitrile/water with a flow rate of 1 ml/min in a reversed-phase was used.MP903, amine, methoxy
amides 1–8, andMP1108–MP1115were synthesized according to the previous protocols (Majumdar et al., 2012; Váradi et al., 2015).Reagents/solvents:
R = phenyl,m-chlorophenyl,m-bromophenyl, o-iodophenyl, p-iodophenyl,m-trifluoromethyl phenyl,m-fluorophenyl, andm-methyl
phenyl; HATU - 1-[Bis(dimethylamino)methylene]-1H-1,2,3-triazolo[4,5-b]pyridinium 3-oxid hexafluorophosphate, DIPEA - N,N-Dii-
sopropylethylamine, DMF - N,N-Dimethylformamide, and DCM -dichloromethane.
N-((7R,12bS)-3-(cyclopropylmethyl)-9-methoxy-2,3,4,4a,7,7a-hexahydro-1H-4,12-methanobenzofuro[3,2-e]
isoquinolin-7-yl)benzamide 1;
(20 mg scale, Yield: 51%); 1H NMR (600 MHz, Chloroform-d) d = 7.88 – 7.71 (m, 2H), 7.54 – 7.46 (m, 1H), 7.43 (t, J = 7.6 Hz, 2H), 6.75
(d, J = 8.2 Hz, 1H), 6.62 (d, J = 8.2 Hz, 1H), 6.26 (s, 1H), 6.06 – 5.88 (m, 1H), 5.65 (dd, J = 9.8, 1.9 Hz, 1H), 4.97 (s, 1H), 4.70 (s, 1H), 4.20
(s, 1H), 3.88 (s, 3H), 3.54 (s, 1H), 3.38 (d, J = 12.6 Hz, 1H), 3.14 – 2.90 (m, 2H), 2.80 (br, 2H), 2.41 (td, J = 13.3, 4.7 Hz, 1H), 2.08 – 1.88
(m, 1H), 1.19 – 1.06 (m, 1H), 0.76 (d, J = 8.0 Hz, 2H), 0.50 – 0.31 (m, 2H). 13C NMR (151 MHz, CDCl3) d = 167.54, 146.16, 143.25,
133.66, 131.96, 130.62, 129.72, 128.95, 128.78, 128.14, 127.19, 119.55, 114.84, 91.98, 60.12, 58.69, 56.84, 49.88, 46.67, 43.55,
21.85, 6.93, 4.53, 4.51. ESI-MS m/z: 443.41 [M+H]+.
3-Chloro-N-((7R,12bS)-3-(cyclopropylmethyl)-9-methoxy-2,3,4,4a,7,7a-hexahydro-1H-4,12-methanobenzofuro[3,2-
e]isoquinolin-7-yl)benzamide 2;
(21mg scale, Yield: 50%); 1HNMR (600MHz, Chloroform-d) d = 7.77 (t, J = 1.9 Hz, 1H), 7.64 (dt, J = 7.7, 1.3 Hz, 1H), 7.47 (ddd, J = 8.0,
2.1, 1.0 Hz, 1H), 7.37 (t, J = 7.9 Hz, 1H), 6.71 (d, J = 8.2 Hz, 1H), 6.58 (d, J = 8.2 Hz, 1H), 6.12 (s, 1H), 6.03 – 5.84 (m, 1H), 5.70 (dd,
J = 9.8, 1.9 Hz, 1H), 4.93 (t, J = 1.2 Hz, 1H), 4.66 (t, J = 6.6 Hz, 1H), 3.95 (d, J = 5.5 Hz, 1H), 3.88 (s, 3H), 3.32 (s, 1H), 3.05 (dd, J = 42.3,
15.6 Hz, 2H), 2.70 (d, J = 36.3 Hz, 2H), 2.61 – 2.45 (m, 2H), 2.25 (td, J = 13.0, 4.5 Hz, 1H), 2.00 – 1.78 (m, 1H), 1.01 (t, J = 6.5 Hz, 1H),
0.65 (dd, J = 7.0, 3.5 Hz, 2H), 0.28 (d, J = 4.9 Hz, 2H). 13C NMR (151MHz, CDCl3) d = 165.95, 146.10, 142.75, 135.74, 134.88, 134.26,
131.87, 130.08, 129.84, 129.57, 127.54, 125.15, 123.49, 119.24, 114.23, 92.16, 60.02, 57.46, 56.81, 50.16, 46.04, 44.21, 34.97,
21.30, 8.23, 4.32, 4.22. ESI-MS m/z: 477.41 [M+H]+.
3-Bromo-N-((7R,12bS)-3-(cyclopropylmethyl)-9-methoxy-2,3,4,4a,7,7a-hexahydro-1H-4,12-methanobenzofuro[3,2-
e]isoquinolin-7-yl)benzamide 3;
(23mg scale, Yield: 50%); 1HNMR (600MHz, Chloroform-d) d = 7.93 (t, J = 1.8 Hz, 1H), 7.69 (dt, J = 7.9, 1.3 Hz, 1H), 7.64 (ddd, J = 8.0,
2.0, 1.0 Hz, 1H), 7.33 (t, J = 7.9 Hz, 1H), 6.71 (d, J = 8.2 Hz, 1H), 6.58 (d, J = 8.2 Hz, 1H), 6.08 – 5.85 (m, 2H), 5.70 (dd, J = 9.7, 2.0 Hz,
1H), 4.93 (t, J = 1.2 Hz, 1H), 4.66 (d, J = 6.8 Hz, 1H), 3.89 (s, 4H), 3.24 (s, 1H), 3.05 – 2.99 (m, 2H), 2.66 (d, J = 32.3 Hz, 2H), 2.53
(d, J = 20.2 Hz, 2H), 2.29 – 2.14 (m, 1H), 1.92 (d, J = 12.8 Hz, 1H), 1.00 (d, J = 7.1 Hz, 0H), 0.73 – 0.57 (m, 2H), 0.27 (d, J = 5.0 Hz,
2H). 13C NMR (151 MHz, CDCl3) d = 165.80, 146.18, 142.70, 135.93, 134.83, 130.40, 130.35, 129.91, 129.49, 125.59, 123.50,
122.93, 119.19, 114.20, 92.19, 60.19, 57.48, 56.83, 50.12, 46.04, 44.30, 39.60, 21.21, 8.43, 4.27, 4.20. ESI-MS m/z: 521.38 [M+H]+.
N-((7R,12bS)-3-(cyclopropylmethyl)-9-methoxy-2,3,4,4a,7,7a-hexahydro-1H-4,12-methanobenzofuro[3,2-e]
isoquinolin-7-yl)-2-iodobenzamide 4;
(15 mg scale, Yield: 30%); 1H NMR (600MHz, Chloroform-d) d = 7.85 (dd, J = 8.0, 1.1 Hz, 1H), 7.51 – 7.32 (m, 2H), 7.18 – 7.02 (m, 1H),
6.70 (d, J = 8.2 Hz, 1H), 6.57 (d, J = 8.2 Hz, 1H), 5.99 (ddd, J = 9.6, 4.9, 1.9 Hz, 1H), 5.68 (dt, J = 14.6, 7.3 Hz, 2H), 5.07 (s, 1H), 4.67
(s, 1H), 3.89 (s, 4H), 3.16 (s, 1H), 2.99 (d, J = 18.7 Hz, 2H), 2.61 – 2.51 (m, 4H), 2.26 (s, 1H), 1.93 (d, J = 12.7 Hz, 1H), 0.95 (s, 1H), 0.61
(s, 2H), 0.24 (s, 2H). 13C NMR (151 MHz, CDCl3) d = 169.04, 146.26, 142.58, 141.61, 139.88, 131.45, 129.05, 128.58, 128.41, 119.12,
114.31, 92.54, 91.92, 60.03, 57.20, 56.92, 50.08, 45.94, 44.37, 40.39, 35.17, 21.15, 8.52, 4.27, 4.07. ESI-MS m/z: 569.32 [M+H]+.
N-((7R,12bS)-3-(cyclopropylmethyl)-9-methoxy-2,3,4,4a,7,7a-hexahydro-1H-4,12-methanobenzofuro[3,2-e] 
isoquinolin-7-yl)-4-iodobenzamide 5;
(18 mg scale, Yield: 36%); 1H NMR (600 MHz, Chloroform-d) d = 7.85 – 7.74 (m, 2H), 7.53 – 7.39 (m, 2H), 6.69 (d, J = 8.2 Hz, 1H), 6.55 
(d, J = 8.1 Hz, 1H), 6.00 – 5.86 (m, 2H), 5.71 (dd, J = 9.7, 2.0 Hz, 1H), 4.91 (d, J = 1.2 Hz, 1H), 4.64 (t, J = 6.6 Hz, 1H), 3.88 (s, 3H), 3.75 
(s, 1H), 3.16 (s, 1H), 2.97 (d, J = 18.5 Hz, 1H), 2.88 (d, J = 12.4 Hz, 1H), 2.49 (dd, J = 16.3, 6.5 Hz, 2H), 2.41 – 2.27 (m, 2H), 2.08 (d, J = 
49.8 Hz, 1H), 1.87 (d, J = 12.6 Hz, 1H), 0.92 (s, 1H), 0.58 (dd, J = 8.0, 2.7 Hz, 2H), 0.19 (d, J = 5.2 Hz, 2H). 13C NMR (151 MHz, CDCl3) 
d = 166.31, 146.22, 142.36, 137.89, 137.17, 133.67, 133.54, 131.38, 130.48, 129.06, 128.67, 123.42, 118.98, 113.86, 98.79, 92.39, 
59.97, 56.82, 56.65, 50.09, 45.56, 44.69, 40.29, 36.02, 20.81, 9.12, 4.15, 3.99. ESI-MS m/z: 569.32 [M+H]+.
N-((7R,12bS)-3-(cyclopropylmethyl)-9-methoxy-2,3,4,4a,7,7a-hexahydro-1H-4,12-methanobenzofuro[3,2-e] 
isoquinolin-7-yl)-3-(trifluoromethyl)benzamide 6;
(30 mg scale, Yield: 66%); 1H NMR (600 MHz, Chloroform-d) d = 8.06 (s, 1H), 7.96 (d, J = 7.8 Hz, 1H), 7.80 – 7.68 (m, 1H), 7.59 (t, J = 
7.8 Hz, 1H), 6.72 (d, J = 8.2 Hz, 1H), 6.58 (d, J = 8.2 Hz, 1H), 6.08 (s, 1H), 5.98 (ddd, J = 9.9, 6.1, 3.4 Hz, 1H), 5.72 (dd, J = 9.7, 1.9 Hz, 
1H), 4.95 (d, J = 1.3 Hz, 1H), 4.76 – 4.48 (m, 1H), 3.89 (s, 4H), 3.27 (s, 1H), 3.11 – 2.91 (m, 2H), 2.67 (d, J = 34.3 Hz, 2H), 2.54 (d, J = 
24.2 Hz, 2H), 2.23 (s, 1H), 1.93 (d, J = 12.9 Hz, 1H), 1.00 (s, 1H), 0.65 (d, J = 8.0 Hz, 2H), 0.34 – 0.20 (m, 3H). 13C NMR (151 MHz, CDCl3) 
d = 165.83, 146.14, 142.74, 134.75, 131.39, 131.18, 130.24, 129.41, 128.45, 124.65, 124.37, 124.35, 122.84, 119.23, 114.19, 92.14, 
60.19, 57.52, 56.81, 50.22, 46.06, 44.28, 39.57, 35.18, 21.21, 8.38, 4.27, 4.21. ESI-MS m/z: 511.41 [M+H]+.
N-((7R,12bS)-3-(cyclopropylmethyl)-9-methoxy-2,3,4,4a,7,7a-hexahydro-1H-4,12-methanobenzofuro[3,2-e] 
isoquinolin-7-yl)-3-fluorobenzamide 7;
(27 mg scale, Yield: 66%); 1H NMR (600 MHz, Chloroform-d) d = 7.52 (ddt, J = 7.7, 4.2, 1.6 Hz, 2H), 7.42 (td, J = 8.0, 5.4 Hz, 1H), 7.20 
(ddd, J = 8.3, 2.6, 1.0 Hz, 1H), 6.72 (d, J = 8.2 Hz, 1H), 6.58 (d, J = 8.2 Hz, 1H), 6.03 – 5.84 (m, 2H), 5.70 (dd, J = 9.8, 2.0 Hz, 1H), 4.94 
(t, J = 1.2 Hz, 1H), 4.67 (s, 1H), 3.89 (s, 4H), 3.26 (s, 1H), 3.12 – 2.89 (m, 2H), 2.68 (d, J = 34.7 Hz, 2H), 2.53 (s, 2H), 2.23 (s, 1H), 1.94 
(d, J = 13.0 Hz, 1H), 1.05 – 0.96 (m, 0H), 0.66 (d, J = 8.0 Hz, 2H), 0.28 (s, 2H). 13C NMR (151 MHz, CDCl3) d = 165.97, 163.67, 162.02, 
146.21, 142.73, 136.24, 136.19, 130.49, 130.44, 129.59, 122.49, 122.47, 119.20, 118.97, 118.83, 114.68, 114.53, 114.27, 92.15, 
60.22, 57.58, 56.84, 50.04, 46.09, 44.25, 35.34, 20.17, 8.34, 4.27, 4.22. ESI-MS m/z: 461.43 [M+H]+.
N-((7R,12bS)-3-(cyclopropylmethyl)-9-methoxy-2,3,4,4a,7,7a-hexahydro-1H-4,12-methanobenzofuro[3,2-e] 
isoquinolin-7-yl)-3-methylbenzamide 8;
(21 mg scale, Yield: 51%); 1H NMR (600 MHz, Chloroform-d) d = 7.58 (s, 1H), 7.56 – 7.44 (m, 1H), 7.40 – 7.29 (m, 2H), 6.69 (d, J = 
8.2 Hz, 1H), 6.55 (d, J = 8.1 Hz, 1H), 6.00 – 5.84 (m, 2H), 5.71 (dd, J = 9.7, 2.0 Hz, 1H), 4.93 (d, J = 1.2 Hz, 1H), 4.66 (s, 1H), 3.89 
(s, 3H), 3.77 (s, 1H), 3.16 (d, J = 15.1 Hz, 1H), 2.98 (d, J = 18.5 Hz, 1H), 2.92 (br, 1H), 2.52 (d, J = 13.1 Hz, 2H), 2.41– 2.30 (m, 5H), 
2.14 (s, 1H), 1.93 – 1.80 (m, 1H), 0.94 (t, J = 5.1 Hz, 1H), 0.59 (d, J = 7.6 Hz, 2H), 0.27 – 0.12 (m, 2H). 13C NMR (151 MHz, CDCl3) 
d = 167.30, 146.28, 142.40, 138.60, 134.08, 132.53, 130.48, 129.41, 128.58, 127.74, 124.02, 118.93, 113.98, 92.49, 60.06, 56.87, 
49.97, 45.68, 44.64, 40.20, 35.91, 21.44, 20.90, 9.06, 4.16, 4.04. ESI-MS m/z: 457.47 [M+H]+.
N-((7R,12bS)-3-(cyclopropylmethyl)-9-hydroxy-2,3,4,4a,7,7a-hexahydro-1H-4,12-methanobenzofuro[3,2-e] 
isoquinolin-7-yl)benzamide MP1108;
(3.7 mg scale, Yield: 24%); 1H NMR (600 MHz, Chloroform-d) d = 7.80 – 7.67 (m, 2H), 7.57 – 7.48 (m, 1H), 7.43 (t, J = 7.6 Hz, 2H), 6.70 
(d, J = 8.1 Hz, 1H), 6.51 (d, J = 8.1 Hz, 1H), 6.05 (s, 1H), 5.91 (ddd, J = 9.4, 5.9, 3.1 Hz, 1H), 5.79 – 5.63 (m, 1H), 4.97 – 4.80 (m, 1H), 4.63 
(t, J = 6.5 Hz, 1H), 3.80 (s, 1H), 3.30 – 3.08 (m, 1H), 2.95 (d, J = 18.6 Hz, 2H), 2.54 (d, J = 35.2 Hz, 2H), 2.47 – 2.27 (m, 2H), 2.15 (s, 1H), 
1.86 (t, J = 14.2 Hz, 1H), 0.90 – 0.74 (m, 1H), 0.58 (d, J = 7.1 Hz, 2H), 0.29 – 0.14 (m, 2H). 13C NMR (151 MHz, CDCl3) d = 167.42, 144.56, 
138.37, 133.90, 131.91, 129.90, 128.74, 127.09, 119.47, 116.79, 93.03, 59.91, 56.86, 50.36, 45.74, 44.69, 30.65, 30.12, 29.80, 27.01, 
20.85, 8.85, 4.20, 4.11. ESI-MS m/z: 429.41 [M+H]+. HRMS calcd for C27H29N2O3 [M+H]+, 429.2178; found, 429.2167.
3-Chloro-N-((7R,12bS)-3-(cyclopropylmethyl)-9-hydroxy-2,3,4,4a,7,7a-hexahydro-1H-4,12-methanobenzofuro[3,2-e] 
isoquinolin-7-yl)benzamide MP1109;
(6.8 mg scale, Yield: 37%); 1H NMR (600 MHz, Chloroform-d) d = 7.76 (t, J = 1.9 Hz, 1H), 7.64 (dt, J = 7.8, 1.3 Hz, 1H), 7.45 (ddd, J = 
8.0, 2.1, 1.0 Hz, 1H), 7.33 (t, J = 7.8 Hz, 1H), 6.71 (d, J = 8.1 Hz, 1H), 6.51 (d, J = 8.1 Hz, 1H), 6.35 (s, 1H), 5.96 – 5.80 (m, 1H), 5.71 (dd, 
J = 9.8, 1.9 Hz, 1H), 4.86 (d, J = 1.2 Hz, 1H), 4.61 (t, J = 6.5 Hz, 1H), 3.88 (d, J = 5.3 Hz, 1H), 3.33 (s, 1H), 2.98 (dd, J = 27.6, 15.3 Hz, 2H), 
2.64 – 2.57 (m, 2H), 2.44 (ddd, J = 37.6, 16.1, 8.6 Hz, 2H), 2.23 (s, 1H), 1.81 (dt, J = 12.5, 2.7 Hz, 1H), 1.01 (s, 1H), 0.60 (ddd, J = 11.9, 
8.5, 5.1 Hz, 2H), 0.24 (p, J = 4.4 Hz, 2H). 13C NMR (151 MHz, CDCl3) d = 166.22, 144.48, 138.72, 135.67, 134.84, 131.87, 130.02, 
129.67, 128.75, 127.57, 125.28, 119.60, 117.26, 92.77, 59.75, 56.94, 50.60, 45.91, 44.44, 39.33, 34.94, 20.99, 8.43, 4.33, 4.21. 
ESI-MS m/z: 463.35 [M+H]+.HRMS calcd for C27H28ClN2O3 [M+H]+, 463.1788; found, 463.1778.
3-Bromo-N-((7R,12bS)-3-(cyclopropylmethyl)-9-hydroxy-2,3,4,4a,7,7a-hexahydro-1H-4,12-methanobenzofuro[3,2-e] 
isoquinolin-7-yl)benzamide MP1110;
(4.2 mg scale, Yield: 22%); 1H NMR (600 MHz, Chloroform-d) d = 7.93 (t, J = 1.8 Hz, 1H), 7.71 (dd, J = 7.9, 1.4 Hz, 1H), 7.62 (ddd, J = 
7.9, 2.0, 1.0 Hz, 1H), 7.29 (t, J = 7.9 Hz, 1H), 6.72 (d, J = 8.1 Hz, 1H), 6.53 (d, J = 8.1 Hz, 1H), 6.31 (s, 1H), 5.89 (ddd, J = 9.5, 5.9, 3.2 Hz, 
1H), 5.76 – 5.59 (m, 1H), 4.96 – 4.80 (m, 1H), 4.63 (t, J = 6.5 Hz, 1H), 3.93 (s, 1H), 3.46 (d, J = 38.6 Hz, 1H), 3.01 (dd, J = 54.0, 14.6 Hz, 
2H), 2.65 (d, J = 37.4 Hz, 2H), 2.54 – 2.45 (m, 2H), 2.30 (s, 1H), 1.90 – 1.80 (m, 1H), 1.07 (s, 1H), 0.64 (d, J = 8.0 Hz, 2H), 0.39 – 0.16 
(m, 2H). 13C NMR (151 MHz, CDCl3) d = 166.11, 144.41, 138.79, 135.80, 134.86, 130.45, 130.30, 129.50, 128.93, 125.78, 122.89, 
119.67, 117.31, 92.80, 59.68, 57.03, 50.59, 46.05, 44.33, 38.93, 34.65, 30.12, 21.10, 8.18, 4.46, 4.32. ESI-MS m/z: 507.32 
[M+H]+. HRMS calcd for C27H28BrN2O3 [M+H]+, 507.1283; found, 507.1259.
N-((7R,12bS)-3-(cyclopropylmethyl)-9-hydroxy-2,3,4,4a,7,7a-hexahydro-1H-4,12-methanobenzofuro[3,2-e]
isoquinolin-7-yl)-2-iodobenzamide MP1111;
(3.6 mg scale, Yield: 34%); 1H NMR (600MHz, Chloroform-d) d = 7.85 (d, J = 7.9 Hz, 1H), 7.47 – 7.34 (m, 2H), 7.11 (td, J = 7.7, 1.7 Hz,
1H), 6.69 (d, J = 8.1 Hz, 1H), 6.50 (d, J = 8.1 Hz, 1H), 5.98 – 5.87 (m, 2H), 5.81 – 5.57 (m, 1H), 5.05 (s, 1H), 4.63 (t, J = 6.6 Hz, 1H), 3.79
(s, 1H), 3.22 – 3.05 (m, 1H), 2.95 (d, J = 18.5 Hz, 2H), 2.39 (t, J = 83.9 Hz, 5H), 1.89 (d, J = 11.7 Hz, 1H), 1.02 – 0.74 (m, 1H), 0.58 (s, 2H),
0.20 (s, 2H). 13C NMR (151MHz, CDCl3) d = 169.19, 144.62, 141.42, 139.90, 138.31, 131.52, 128.78, 128.36, 128.01, 119.50, 116.80,
92.49, 59.81, 56.70, 50.35, 45.73, 44.70, 30.12, 20.88, 8.71, 4.26, 4.10. ESI-MS m/z: 555.32 [M+H]+. HRMS calcd for C27H28IN2O3
[M+H]+, 555.1145; found, 555.1147.
N-((7R,12bS)-3-(cyclopropylmethyl)-9-hydroxy-2,3,4,4a,7,7a-hexahydro-1H-4,12-methanobenzofuro[3,2-e]
isoquinolin-7-yl)-4-iodobenzamide MP1112;
(3.1 mg scale, Yield: 22%); 1H NMR (600 MHz, Chloroform-d) d = 7.76 (d, J = 8.3 Hz, 2H), 7.49 (d, J = 8.4 Hz, 2H), 6.70 (d, J = 8.1 Hz,
1H), 6.52 (d, J = 8.1 Hz, 1H), 6.11 (s, 1H), 5.88 (ddd, J = 9.5, 6.1, 3.2 Hz, 1H), 5.72 (dd, J = 9.8, 1.9 Hz, 1H), 4.85 (d, J = 1.2 Hz, 1H), 4.60
(t, J = 6.5 Hz, 1H), 3.83 (s, 1H), 3.21 (d, J = 39.8 Hz, 1H), 2.95 (d, J = 18.6 Hz, 2H), 2.64 – 2.47 (m, 2H), 2.47 – 2.28 (m, 2H), 2.18 (s, 1H),
1.89 – 1.78 (m, 1H), 1.04 – 0.88 (m, 1H), 0.59 (d, J = 6.5 Hz, 2H), 0.26 – 0.16 (m, 2H). 13C NMR (151 MHz, CDCl3) d = 166.68, 144.53,
138.46, 137.93, 133.29, 129.81, 128.73, 128.62, 119.57, 116.96, 98.98, 92.88, 59.86, 56.85, 50.42, 45.78, 44.63, 39.70, 35.38, 30.13,
20.88, 8.71, 4.25, 4.16. ESI-MS m/z: 555.25 [M+H]+. HRMS calcd for C27H28IN2O3 [M+H]
+, 555.1145; found, 555.1125.
N-((7R,12bS)-3-(cyclopropylmethyl)-9-hydroxy-2,3,4,4a,7,7a-hexahydro-1H-4,12-methanobenzofuro[3,2-e]
isoquinolin-7-yl)-3-(trifluoromethyl)benzamide MP1113;
(6.1 mg scale, Yield: 24%); 1H NMR (600 MHz, Chloroform-d) d = 8.04 (s, 1H), 7.96 (d, J = 7.8 Hz, 1H), 7.84 – 7.67 (m, 1H), 7.55 (t, J =
7.8 Hz, 1H), 6.70 (d, J = 8.1 Hz, 1H), 6.51 (d, J = 8.1 Hz, 1H), 6.27 (s, 1H), 5.90 (ddd, J = 9.5, 6.0, 3.1 Hz, 1H), 5.78 – 5.63 (m, 1H), 4.88
(t, J = 1.1 Hz, 1H), 4.63 (t, J = 6.5 Hz, 1H), 3.84 (s, 1H), 3.22 (d, J = 51.5 Hz, 1H), 2.95 (d, J = 18.2 Hz, 2H), 2.56 (d, J = 36.6 Hz, 2H), 2.46 –
2.26 (m, 2H), 2.19 (s, 1H), 1.88 – 1.73 (m, 1H), 0.97 (s, 1H), 0.63 – 0.53 (m, 2H), 0.25 – 0.16 (m, 2H). 13C NMR (151 MHz, CDCl3)
d = 166.07, 144.45, 138.49, 134.70, 131.37, 131.15, 130.41, 129.78, 129.37, 128.47, 124.61, 124.28, 124.25, 122.80, 119.60,
117.02, 92.81, 59.84, 56.87, 50.66, 45.79, 44.60, 35.26, 30.12, 20.89, 8.68, 4.25, 4.13. ESI-MS m/z: 497.42 [M+H]+. HRMS calcd
for C28H28F3N2O3 [M+H]
+, 497.2052; found, 497.2060.
N-((7R,12bS)-3-(cyclopropylmethyl)-9-hydroxy-2,3,4,4a,7,7a-hexahydro-1H-4,12-methanobenzofuro[3,2-e]
isoquinolin-7-yl)-3-fluorobenzamide MP1114;
(4.8 mg scale, Yield: 22%); 1H NMR (600MHz, Chloroform-d) d = 7.57 – 7.43 (m, 2H), 7.38 (td, J = 8.1, 5.6 Hz, 1H), 7.23 – 7.10 (m, 1H),
6.70 (d, J = 8.1 Hz, 1H), 6.51 (d, J = 8.1 Hz, 1H), 6.22 (s, 1H), 5.88 (ddd, J = 9.8, 4.7, 2.0 Hz, 1H), 5.72 (dd, J = 9.8, 1.9 Hz, 1H), 4.87
(d, J = 1.2 Hz, 1H), 4.61 (t, J = 6.5 Hz, 1H), 3.97 – 3.75 (m, 1H), 3.28 (s, 1H), 2.96 (d, J = 18.6 Hz, 2H), 2.58 (d, J = 38.4Hz, 2H), 2.51 – 2.35
(m, 2H), 2.21 (s, 1H), 1.83 (dt, J = 12.8, 2.8 Hz, 1H), 1.04 – 0.94 (m, 1H), 0.60 (t, J = 6.7 Hz, 2H), 0.23 (q, J = 4.5 Hz, 2H). 13C NMR
(151 MHz, CDCl3) d = 166.23, 163.62, 161.98, 144.53, 138.57, 136.18, 130.42, 130.37, 129.74, 128.69, 122.61, 122.59, 119.57,
118.96, 118.82, 117.10, 114.71, 114.56, 92.79, 59.80, 56.89, 50.52, 45.83, 44.54, 39.52, 30.12, 20.93, 8.57, 4.28, 4.17. ESI-MS
m/z: 447.43 [M+H]+. HRMS calcd for C27H28FN2O3 [M+H]
+, 447.2084; found, 447.2076.
N-((7R,12bS)-3-(cyclopropylmethyl)-9-hydroxy-2,3,4,4a,7,7a-hexahydro-1H-4,12-methanobenzofuro[3,2-e]
isoquinolin-7-yl)-3-methylbenzamide MP1115;
(3.5 mg scale, Yield: 38%); 1H NMR (600 MHz, Chloroform-d) d = 7.58 (s, 1H), 7.54 (dt, J = 4.2, 2.1 Hz, 1H), 7.32 (dd, J = 4.6, 2.2 Hz,
2H), 6.69 (d, J = 8.1 Hz, 1H), 6.51 (d, J = 8.1 Hz, 1H), 5.97 (s, 1H), 5.94 – 5.87 (m, 1H), 5.73 (dd, J = 9.8, 1.9 Hz, 1H), 4.89 (d, J = 1.2 Hz,
1H), 4.62 (t, J = 6.6 Hz, 1H), 3.78 (s, 1H), 3.14 (s, 1H), 2.93 (t, J = 19.1 Hz, 2H), 2.51 (d, J = 27.9 Hz, 2H), 2.40 (b, 5H), 2.12 (s, 1H), 1.91 –
1.78 (m, 1H), 1.02 – 0.88 (m, 1H), 0.58 (d, J = 7.0 Hz, 2H), 0.20 (s, 2H). 13C NMR (151MHz, CDCl3) d = 167.57, 144.55, 138.63, 138.28,
133.87, 132.66, 129.98, 128.74, 128.62, 127.75, 124.08, 119.43, 116.68, 93.12, 59.94, 56.82, 50.31, 45.70, 44.76, 40.02, 35.69,
21.46, 20.81, 8.99, 4.17, 4.07. ESI-MS m/z: 443.41 [M+H]+. HRMS calcd for C28H31N2O3 [M+H]
+, 443.2335; found, 443.2321.
N-((4aS,7R,12bS)-3-allyl-4a,9-dihydroxy-2,3,4,4a,5,6,7,7a-octahydro-1H-4,12-methanobenzofuro[3,2-e]isoquinolin-
7-yl)-4-fluoro-3-iodobenzamide MP903;
(Yield: 68%); 1H NMR (600MHz, Chloroform-d) d = 8.23 (dd, J = 5.9, 2.2 Hz, 1H), 7.78 (ddd, J = 8.5, 4.8, 2.2 Hz, 1H), 7.35 (d, J = 9.0 Hz,
1H), 7.07 (dd, J = 8.5, 7.5 Hz, 1H), 6.68 (d, J = 8.1 Hz, 1H), 6.58 (d, J = 8.1 Hz, 1H), 5.81 (ddt, J = 16.7, 10.1, 6.4 Hz, 1H), 5.27 – 5.09
(m, 2H), 4.58 (d, J = 5.6 Hz, 1H), 4.11 (dq, J = 9.5, 4.7 Hz, 1H), 3.20 – 3.03 (m, 3H), 2.97 (d, J= 6.0 Hz, 1H), 2.63 (dd, J = 18.4, 6.1 Hz, 1H),
2.55 (d, J = 7.5 Hz, 1H), 2.20 (d, J = 8.1 Hz, 2H), 1.91 (dtd, J = 14.1, 9.1, 5.1 Hz, 1H), 1.68 (dt, J = 14.1, 5.4 Hz, 1H), 1.61 – 1.43 (m, 3H).
13C NMR (151 MHz, CDCl3) d = 164.57, 164.48, 162.82, 142.94, 139.18, 138.86, 135.23, 132.34, 130.60, 129.24, 129.19, 124.92,
119.46, 118.24, 117.56, 115.65, 115.49, 92.76, 81.58, 81.40, 70.31, 62.46, 57.88, 50.49, 47.30, 43.63, 31.75, 29.08, 23.18, 22.95,
22.78. HRMS calcd for C26H27FN2O3 [M+H]
+, 577.1000; found, 577.0988.
QUANTIFICATION AND STATISTICAL ANALYSES
Dose response, log(t/KA) calculation and ligand bias quantification
Bias factor toward G protein was calculated with SalA or DAMGO as a reference agonist. In detail, dose-response data with respect
to reference ligands were fit using the Black and Leff operational model in Graphpad Prism 5.0, where EMAX represents the
maximum response of the system and was set to 100, KA is the functional dissociation constant for the agonist, and t is the efficacy
of the agonist in the given pathway, and n is the slope of the response. Data for MP1104 or IBNtxA was fit globally with reference
ligand responses such that EMAX and n are shared parameters and KA and t are then fit individually for MP1104 or IBNtxA. Trans-
duction coefficients (log (t/KA)) were calculated using the Black and Leff operational model (Black and Leff, 1983) in Graphpad Prism
5.0. Using SalA or DAMGO as the full agonist reference, transduction coefficients for Gi cAMP inhibition and Tango b-Arrestin2 trans-
location were calculated and averaged across experiments (n = 3). Calculation of bias factors utilized the method by Kenakin et al.
(2012), where the Dlog(t/KA) was calculated relative to the reference ligand and the DDlog(t/KA) was calculated by subtracting the Gi
transduction coefficient from the b-Arrestin2 transduction coefficient.
DATA AND SOFTWARE AVAILABILITY
Data Resources
The accession number for the coordinates and structures factors of KOP-MP1104-Nb39 complex reported in this paper is
PDB: 6B73.
Figure S1. Characterization of Inactive- and Active-State-Stabilizing Nanobodies and Pharmacology of MP1104, Related to Figure 1
(A) Screening of nanobodies from the KOP-SalA library using BRET assay. As can be seen, Nb6/7 (blue) shows dose-response upon SalA stimulation (n = 3). Note
that concentration at 12 represents ‘‘no drugs’’ added.
(B) The antagonist JDTic reverses SalA-induced dissociation in a concentration-dependent manner. Cells expressing KOP-Rluc and Nb6-YFP were treated with
0.1 mM SalA for 5 min and then stimulated by increasing concentrations of JDTic for 5 min and BRET signal was measured.
(C) Recruitment of Nb39 to KOP in the presence of full agonist SalA (EC50 = 10.2 ± 0.8 nM, Emax = 100 ± 2, orange), partial agonist diprenorphine (EC50 = 5.20 ±
0.03 nM, Emax = 32 ± 2, blue), or antagonist JDTic (no activity detected, red) (n = 3).
(D) Comparison of U69,593 dissociation rate at KOP only (blue), KOP+Nb6 (green triangle) and KOP+Nb39 (yellow) shows a slow U69,593 off-rate with Nb39 and
a faster off-rate with Nb6 (n = 3).
(E) Interaction of KOP and Nb39 in the presence of Gai1 or b-arrestin2. Using BRET assay, KOP-Rluc and Nb39 were co-transfected with different amounts of
Gai1 or b-arrestin2 (n = 3). See Table S1 for values.
(F) Measurement of MP1104 binding affinity at MOP (Ki = 0.18 ± 0.06 nM, red), KOP (Ki = 0.20 ± 0.08 nM, orange) and DOP (Ki = 1.38 ± 0.05 nM, light green) using
radioligand 3H-Diprenorphine (n = 3).
(G) Measurement of MP1104-mediated Gi activation in KOP (MP1104, EC50 = 0.003 ± 0.001 nM, Emax = 100 ± 2, orange; SalA, EC50 = 0.033 ± 0.008 nM, Emax =
98 ± 2, red), MOP (MP1104, EC50 = 0.034 ± 0.008 nM, Emax = 104 ± 1, orange; DAMGO, EC50 = 3.45 ± 0.06 nM, Emax = 100 ± 2 red) and DOP (MP1104, EC50 =
0.67 ± 0.07 nM, Emax = 97 ± 2 orange; DADLE, EC50 = 1.34 ± 0.05 nM, Emax = 100 ± 2 red) (n = 3).
(legend on next page)
Figure S2. Structural Features Observed in the Active-State KOP, Related to Figures 1 and 2
(A) Confirmation of KOP crystallization construct functionality in binding assays. MP1104 (orange), Ki = 0.33 ± 0.02 nM; SalA (light green), Ki = 25.3 ± 1.40 nM
(n = 3).
(B) Confirmation of KOP crystallization construct functionality in cAMP inhibition assays. MP1104 (orange), EC50 = 0.006 ± 0.001 nM; SalA (light green), EC50 =
0.26 ± 0.02 nM (n = 3).
(C) Crystal packing of KOP-MP1104-Nb39 complex. KOP (blue), Nb39 (orange), MP1104 (orange sphere).
(D) Crystal contacts within anti-parallel monomers (top) or parallel dimers (bottom). The KOP-MP1104-Nb39 complex displays an anti-parallel receptor dimer in
the asymmetric unit through interactions between ECL2 and intracellular loop 2 (ICL2) of the two monomers (D218ECL2—H1623.56/P163ICL2). Parallel dimers are
observed within the crystal lattice with dimer interfaces formed by TM1 and TM2 residues.
(E) Electron density of MP1104 and ligand binding pocket residues. (left) Different angles showing structure of receptor-boundMP1104 (orange stick model) with
mFo-DFc omit density map contoured at 3s (green mesh). (middle) Different angles showing structure of receptor-bound MP1104 (orange stick model) with
2mFo-DFc electron densitymap contoured at 1s (bluemesh). (right) Different angles showing structure of ligand binding pocket residueswith 2mFo-DFc electron
density map contoured at 1s (blue mesh). All density maps were generated in Refmac5. Interactions between ligand and receptor residues result in continuous
2mFo-DFc density that appears ‘‘broken’’ when only receptor or ligand density is displayed. Grey dots indicate Hydrogen-bonds between receptor and ligand.
(F) Comparison of inactive and active-state b2AR or M2R indicates a common contraction during activation. Distances were measured between the Ca atoms of
M401.39, S2035.42, and F2906.52, N3127.39 in b2AR; I26
1.35, V4076.55, I417ECL3, and N4197.32 in M2R.
(G and H) Residues within KOP-Nb39 interface (G) indicate they are highly conserved among the three canonical opioid receptors (H).
Figure S3. Interactions between MP1104 and Binding Pocket Residues, Related to Figure 3
(A) Mutagenesis studies indicate that KOP T1112.56 and Y3207.43 residues are crucial for full activation of KOP. KOPwt (MP1104, EC50 = 0.035 ± 0.005 nM, Emax =
100 ± 2; Dynorphin A, EC50 = 12.60 ± 1.15 nM, Emax = 75 ± 3). KOP T111
2.56A (MP1104, EC50 = 3.50 ± 0.23 nM, Emax = 93 ± 3; Dynorphin A, EC50 = 12.30 ±
1.05 nM, Emax = 30 ± 2). KOP Y320
7.43A (MP1104, EC50 = 10.20 ± 0.89 nM, Emax = 91 ± 2; Dynorphin A, no activity detected). (n = 3).
(B) Comparison of water-mediated interactions with the phenol group between KOP and MOP. Active state KOP residues are shown in blue sticks, and blue
cartoon representation. Active stateMOP (PDB ID: 5C1M) residues are shown in green sticks. MP1104 and BU-72 are shown in orange and green colored carbon
sticks respectively. Crystallographic waters in active MOP (from 5C1M) are shown in green balls, and calculated waters in KOP are represented by blue balls.
Water mediated hydrogen bonds common to both KOP and MOP are shown in black broken lines, while water mediated hydrogen bonds specific for MOP are
shown in red broken lines.
(C) The MP1104 analog, MP1107, causes more severe reduction of binding affinity in MOP than in KOP. Chemical differences between compound structures are
highlighted in red. MP1104 (red), Ki = 0.20 ± 0.02 nM in KOP (top) and 0.16 ± 0.03 nM in MOP (bottom); MP1107 (orange), Ki = 1.07 ± 0.06 nM in KOP (top) and
5.85 ± 0.08 nM in MOP (bottom) (n = 3).
(D) Removal of the cyclopropyl group reducesMP1104’s functional activity in KOP. Chemical differences between compound structures are highlighted in red. Gi
activation (top): MP1104 (red), EC50 = 0.003 ± 0.001 nM, Emax = 97 ± 1; MP1101 (orange), EC50 = 0.055 ± 0.010 nM; Emax = 98 ± 1. b-Arrestin2 recruitment
(bottom): MP1104 (red), EC50 = 0.043 ± 0.010 nM, Emax = 113 ± 2; MP1101 (orange), EC50 = 0.41 ± 0.08 nM, Emax = 111 ± 2 (n = 3).
(E) Docking of MP1104 (orange) in the active structure of MOP (green) indicates the cyclopropylmethyl group also extends into the hydrophobic pocket.
Figure S4. Characterization of Functional Bias of IBNtxA and Its Analogs, Related to Figure 5
(A) GTPg[35S] (top panel) and BRET (arrestin recruitment) (bottom panel) activities indicates that KOP Y3127.35W recapitulates IBNtxA’s biased activity in
MOP. Bias factor toward G protein in MOP was calculated with DAMGO as a reference agonist based on the Black and Leff operational model and defined as
10DDLog(t/KA): 0.8 and 9 for MP1104 and IBNtxA, respectively (n = 3). See Table S5 for values.
(B) Comparison of IBNtxA (gray) and MP1104 (orange) docking in MOP indicates that the iodobenzamide group adopts different orientations.
(C) Chemical structures and arrestin recruitment activity of IBNtxA analogswith a single bond in the saturated ring (highlighted in red). (left) Arrestin activity in KOP:
MP903 (red), EC50 = 0.074 ± 0.012 nM, Emax = 108 ± 10; IBNtxA (orange), EC50 = 0.030 ± 0.009 nM, Emax = 95 ± 8; MP970 (light green), EC50 = 0.16 ± 0.04 nM,
Emax = 92 ± 6; MP1104 (green), EC50 = 0.037 ± 0.008 nM, Emax = 100 ± 2. (right) Arrestin activity in MOP: MP903 (red), EC50 = 0.12 ± 0.05 nM, Emax = 33 ± 5;
IBNtxA (orange), EC50 = 0.075 ± 0.008 nM, Emax = 25 ± 6; MP970 (light green), EC50 = 0.54 ± 0.10 nM, Emax = 21 ± 5; MP1104 (green), EC50 = 0.55 ± 0.08 nM,
Emax = 100 ± 2 (n = 3). Bias factor toward G protein: 10.3 and 9 for MP903 and MP970, respectively.
Figure S5. Structure-Activity Relationship Analysis Identifies Structural Features for Ligand Selectivity, Related to Figure 5
(A) Docking poses of U69,593 and U50,488 in the active state KOP-MP1104-Nb39 structure.
(B) Putative binding mode for SalA in the KOP-MP1104-Nb39 structure.
(C) Chemical structures and binding affinity of MP1104 analogs with modifications in the iodobenzamide group. Kis in KOP (left) and MOP (right) respectively:
MP1104, 0.20 ± 0.06 and 0.16 ± 0.05 nM; MP1108, 0.42 ± 0.05 and 0.42 ± 0.06 nM; MP1109, 0.13 ± 0.03 and 0.16 ± 0.05 nM; MP1110, 0.12 ± 0.04 and 0.18 ±
0.04 nM; MP1111, 0.27 ± 0.06 and 0.20 ± 0.05 nM; MP1112, 0.12 ± 0.03 and 0.17 ± 0.03 nM; MP1113, 0.14 ± 0.07 and 0.24 ± 0.06 nM; MP1114, 0.16 ± 0.07 and
0.27 ± 0.08 nM; MP1115, 0.18 ± 0.08 and 0.25 ± 0.06 nM (n = 3).
